  
 
 
Protocol 
 
Study ID: 107116 
 Official Title of Study : A randomised, double -blind, parallel group, multicentre, stratified, study  
evaluating the efficacy and safety of once daily fluticasone furoate/vilanterol inhalation  powder 
compared to once daily fluticasone furoate inhalati on powder in the treatment of asthma in 
participants aged 5 to 17 years old (inclusive) currently uncontrolled on inhaled corticosteroids  
 
EudraCT Identifier : 2016-004086-87 
 
IND Identifier : 077855   
 
Approval Date of Document : 24- AUG -2020  
 
 
2016N298634_04 CONFIDENTIA L
GlaxoSmithKline group of companies HZA107116
1TITLE PA GE
Protocol Title: A randomised, double -blind, parallel group, multicentre, stratified, study  
evaluating the efficacy  and safet y of once dail y fluticasone furoate/vilanterol inhalation 
powder compared to once daily  fluticasone furoate inhalation powder in the treatment of 
asthma in participants aged 5 to 17 y ears old (inclusive) currently uncontrolled on inhaled 
corticosteroids
Protocol Number : HZA107116/04
Short Title : A double -blind, parallel group stud y to evaluate the safet y and efficacy of 
fluticasone furoate/vilanterol combination compared to fluticasone furoate in the 
treatment of asthma in participants 
(aged 5 to 17 years old inclusive )
Compound 
Number:GW685698+ GW642444
Sponsor Name and Legal Registered Address: 
GlaxoSmithKline Research & Development Limited
980 Great West Road
Brentford
Middlesex, TW8 9GS
UK
Medical Monitor Name and Contact Informatio n:  , MD.  Details 
provided in SRM.
Regulatory Agency Identifying Number(s): IND No: 077855; EudraCT No: 2016-
004086-87
Approval Date: 24-AUG - 2020
Copy right 2020 the GlaxoSmithKline group of companies.  All rights reserved.  
Unauthorised cop ying or use of this information is prohibited.
PPD
PPD
PPD
PPD
2016N298634_04 CONFIDENTIA L
HZA107116
3PROTOCOL A MENDMENT SUMMA RY OF CHA NGES TA BLE
DOCUMENT HISTORY
Document Date
Amendment 04 24-AUG -2020
Amendment 0331-JAN-2020
Amendment 0210-DEC -2019
This amendment was not implemented at clinical 
sites. 
Amendment 01 19-JUN-2019
This amendment was not implemented at clinical 
sites. 
Original Protocol 22-JUN-2017
Amendment 04: 24 -AUG -2020
Overall Rationale for the Amendment: The main purpose of this amendment is to 
allow the option for certain visits to either be conducted at home b y a qualified nurse or 
replaced b y video -calls with the site, when appropriate and if permitted by local 
regulations. The screening, randomisation and Visit 6 (serial spirometry ) will continue to 
be done in the clinic.  
Challenges resulting from the COVID -19 pandemic have the potential to impact the 
conduct and delivery  of the study  due to quarantines, site closures and travel limitations.  
The addi tion of these flexible visit options will address some of the challenges faced b y 
sites impacted by  the pandemic and aid study  recruitment and retention by  easing the 
burden on site staff, subjects and parents. 
This amendment also includes other minor edits including clarifications to some of the 
Inclusion/ Exclusion criteria and details for detecting and reporting device deficiencies 
havebeen added to Section 11.2.8 and Appendix 7 . 
Appendix 9 provides details of home nursing and video- calling options are outlined in 
detail in Appendix 9 (COVID -19 Measures ) and the table below summarises the changes 
made in this amendment. 
2016N298634_04 CONFIDENTIA L
HZA107116
4Section # and Name Description of Change Brief Rationale
Protocol Amendment 
and Summary of 
Changes Table Document History updated to include 
Amendment 4.
Minor edits made to the document 
history table.
The rationale for amendment 3 
replaced by the rationale for 
Amendment 4
The table of changes for amendment 3 
moved to this S ection (Appendix 10)Updated to include 
Amendment 4
Table 1: Schedule of 
Activities A row added to the table to indicate 
type of visit e.g. clinic only, home or 
clinic, video -call or clinic etc 
Footnote 1 updated to clarify the run -in 
period for subjects that are re- screened 
and revise the screening window. 
Footnote 2 updated to include options 
of a video -call at Visit 5 and 7 and 
home visit (if spirometry is done) at 
Visits. Reference to direct to patient 
shipment of IP has been included. 
Footnote 12 corrected so that it applies 
to the current visit options available.
Footnote 15 added to clarify that the 
subject should be rescheduled, at the 
earliest opportunity, to collect serial 
spirometry, if it can not be done at the 
visit for any reason.  
Footnote 16 added to refer to the 
option of direct to patient shipment of 
IP that may be available to participants 
who will not be attending the clinic.This S ection has been 
updated to clarifying existi ng 
information and include the 
options of home visits and 
video -calls. 
Figure 1: Study 
SchematicText below the schematic updated to 
reflect the home nursing and 
telemedicine (video -calling options)Updated to reflect the 
additional options of home 
visits and video -calling. 
2016N298634_04 CONFIDENTIA L
HZA107116
5Section # and Name Description of Change Brief Rationale
Section 5.1 Overall 
Study DesignText added to clarify that the run -in 
period is 4 weeks from screening and 
remains 4 weeks, if the spirometry is 
re-tested .
Text updated to include the home visit 
and telemedicine options. Text has b een updated to 
added clarity with regards to 
the run -in period and to 
reflect additional options of 
home visits and video -
calling.
Section 8.1: Inclusion 
Criteria The note relating to criteria 3, updated 
for additional clarity 
Criteria 6 updated to incl ude SAMA in 
the definition of stable asthma therapy 
Criteria 7 updated to include SAMA Some countries use SAMA 
instead of SABA as part of 
their stable asthma therapy 
regime.
Section 8.2: Exclusion 
CriteriaThe unit measurement for fasting 
corrected for the fasting blood glucose 
in criteria 5 Correction of typographical 
error
Section 8.3: Screen 
Failures Clarifying the timing of re -screens 
following a run -in or screen failure Updated for clarification 
Section 11.1.1: FEV1 Section updated and added to reflect 
the home visit options. Updated to reflect the 
additional options of home 
visits
Section 11.1.1.1: 
Serial FEV1Text added to clarify that the subject 
should be rescheduled, at the earliest 
opportu nity, to collect serial spirometry, 
if it cannot be done at the visit for any 
reason.  Updated for clarification 
Section 11.2.8: 
Medical Device 
Deficiencies Section added.  To fulfil regulatory reporting 
obligations worldwide, th is 
Section outlines the PI’s
responsib ilities for the 
detection and documentation 
of events meeting the 
definitions of device 
deficiency that occur during 
the study . 
Appendix 1: 
Abbreviations and 
TrademarksCRO added to the list of abbreviations 
and RELVAR added to the trad emarks 
table. Updated to include an 
abbreviation and trademark 
product used in Appendix 9
Appendix 7: AEs, 
ADEs, SAEs, SADEs, Appendix added . Definition and Procedures 
for Recording, Evaluating, 
2016N298634_04 CONFIDENTIA L
HZA107116
6Section # and Name Description of Change Brief Rationale
USADEs and Device 
Deficiencies: 
Definition and 
Procedures for 
Recording, Evaluating, 
Follow -up, and 
Reporting in Medical 
Device StudiesFollow -up, and Reporting in 
AEs, ADEs, SAEs, SADEs, 
USADEs and Device 
Deficiencies in medical 
device studies added .
Appendix 9: COVID -
19 MeasuresAppendix added. This A ppendix ha s been 
added to outline the changes 
that have been made in 
response to the COVID- 19 
pandemic
Appendix 10: Protocol 
Amendment History This S ection has been updated to 
include the changes made in 
Amendment 4
The Overall Rationale for Amendment 
3 (including the table with the 
description and rationale for the 
changes) moved from the Protocol 
Amendment and Summary of Changes 
Table at the front of the protocol to this 
Section (Appendix 8)
Changes made to S ection 7.7.1 in 
Amendment 3 have been added to the 
table with the description and rationale 
in this S ection (Appendix 10)This S ection includes 
changes made in 
amendment 4 
Detail s of amendment 3 
moved to this S ection 
(Appendix 8) to maintain 
consistency in where 
changes to the protocol are 
being recorded 
In Amendment 3, changes 
made to S ection 7.7.1 
inadvertently excluded from 
the table of changes has 
been added
2016N298634_04 CONFIDENTIA L
HZA107116
7TABLE OF CONTENTS
PAGE
PROTOCOL AMENDMENT S UMMARY OF CHANGES TA BLE..................................... 3
1.SYNOPSIS ............................................................................................................. 10
2.SCHEDULE OF ACTIVITI ES (SOA) ....................................................................... 13
3.INTRODUCTION .................................................................................................... 20
3.1. Study Rationale .......................................................................................... 20
3.2. Background ................................................................................................ 20
3.3. Benefit/Risk Assessment ............................................................................ 21
3.3.1. Risk Assessment FF and FF/VI ................................................... 21
3.3.2. Benefit Assessment ..................................................................... 26
3.3.3. Overall Benefit:Risk Conclusion ................................................... 26
4.OBJECTIVES AND ENDPO INTS ........................................................................... 27
5.STUDY DESIGN .................................................................................................... 28
5.1. Overall Design ............................................................................................ 28
6.NUMBER OF PARTICIPAN TS............................................................................... 30
7.PARTICIPANT AND STUD Y COMPLETION .......................................................... 30
7.1. Scientific Rationale for Study Design .......................................................... 30
7.2. Dose Justification ........................................................................................ 31
8.STUDY POPULATION ........................................................................................... 31
8.1. Inclusion Criteria ......................................................................................... 31
8.2. Exclusion Criteria ........................................................................................ 33
8.3. Screen Failures ........................................................................................... 35
8.4. Randomisation Criteria ............................................................................... 35
8.4.1. Inclusion Criteria for Randomisation to Treatment ....................... 35
8.4.2. Exclusion Criteria for Randomisat ion to Treatment ...................... 36
9.TREATMENTS ....................................................................................................... 36
9.1. Treatments Administered ............................................................................ 36
9.1.1. Medical Devices ........................................................................... 37
9.2. Dose Modification ....................................................................................... 37
9.3. Method of Treatment Assignment ............................................................... 38
9.4. Blinding ....................................................................................................... 38
9.5. Preparation/Handling/Storage/Accountability .............................................. 38
9.6. Treatment Compliance................................................................................ 39
9.7. Concomitant Therapy .................................................................................. 39
9.7.1. Prohibited Medications and Non -Drug Therapies ......................... 40
9.8. Treatment after the End of the Study .......................................................... 41
10.DISCONTINUATION CRIT ERIA ............................................................................. 41
10.1. Discontinuation of Study Treatment ............................................................ 41
10.1.1. Liver Chemistry Stopping Criteria ................................................ 42
10.1.2. QTc Stopping Criteria .................................................................. 44
2016N298634_04 CONFIDENTIA L
HZA107116
810.2. Withdrawal from the Study .......................................................................... 45
10.3. Lost to Follow Up ........................................................................................ 45
11.STUDY ASSESSMENTS AN D PROCEDURES ..................................................... 46
11.1. Efficacy Assessments ................................................................................. 46
11.1.1. FEV 1............................................................................................ 46
11.1.1.1. Serial FEV 1................................................................ .47
11.1.1.2. Reversibility ................................................................ 47
11.1.2. Electronic Daily Diaries ................................................................ 48
11.1.2.1. Daily PEF ................................................................... 48
11.1.2.2. Asthma Symptom Scores ........................................... 48
11.1.3. Questionnaires ............................................................................ 49
11.1.3.1. Childhood Asthma Control Test and Asthma 
Control Test ................................................................ 49
11.1.3.2. Asthma Control Questionnaire ACQ -5........................ 50
11.1.4. Asthma exacerbation ................................................................... 50
11.2. Adverse Events ........................................................................................... 50
11.2.1. Time Period and Frequency for Collecting AE and SAE 
Information ................................................................................... 50
11.2.2. Method of Detectin g AEs and SAEs............................................. 51
11.2.3. Follow -up of AEs and SAEs ......................................................... 51
11.2.4. Regulatory Reporting Requirements for SAEs ............................. 51
11.2.5. Death Events ............................................................................... 52
11.2.6. Pregnancy ................................................................................... 52
11.2.7. Treatment of Overdose ................................................................ 52
11.2.8. Medical Device Defic iencies ........................................................ 53
11.2.8.1. Time Period for Detecting Medical Device 
Deficiencies ................................................................ 53
11.2.8.2. Follow -up of Medical Device Deficiencies ................... 53
11.2.8.3. Prompt Reporting of Medical Device 
Deficiencies to Sponsor .............................................. 53
11.2.8.4. Regulatory Reporting Requirements for 
Medical Device Incidents ............................................ 54
11.3. Safety Assessments ................................................................................... 54
11.3.1. Physical Examination ................................................................... 54
11.3.2. Oropharyngeal Examination ......................................................... 54
11.3.3. Vital Signs .................................................................................... 54
11.3.4. Electrocardiograms ...................................................................... 55
11.3.5. Clinical Safety Laboratory Assessments ...................................... 55
11.4. Pharmacokinetics ....................................................................................... 55
11.5. Pharmacodynamics .................................................................................... 55
11.6. Genetics ..................................................................................................... 55
11.7. Biomarkers ................................................................................................ .56
11.8. Health Economics OR Medical Resource Utilization and Health 
Economics .................................................................................................. 56
12.STATISTICAL CONSIDER ATIONS ........................................................................ 56
12.1. Sample Size Determination ........................................................................ 56
12.1.1. Sample Size Assumptions ........................................................... 56
12.1.1.1. Sample Size Assumptions for 5 -17 Years Old 
Population .................................................................. 56
2016N298634_04 CONFIDENTIA L
HZA107116
912.1.1.2. Sample Size Assumptions for 5-11 Years Old 
Population .................................................................. 56
12.1.2. Sample Size Sensitivity ................................................................ 57
12.1.3. Sample Size Re- estimation .......................................................... 58
12.2. Populations for Analyses ............................................................................ 58
12.3. Statistical Analyses ..................................................................................... 58
12.3.1. Hypotheses .................................................................................. 58
12.3.2. Treatment Comparisons .............................................................. 60
12.3.2.1. Primary Comparison of Interest .................................. 60
12.3.2.2. Other Comparisons of Interest .................................... 60
12.3.3. Key Elements of Analysis Plan .................................................... 61
12.3.3.1. Primary Efficacy Analyses .......................................... 62
12.3.3.1.1. Primary Efficacy Analyses for 5 -17 
Years Old Population .............................. 62
12.3.3.1.2. Primary Efficacy Analyses for 5 -11 
Years Old Population .............................. 62
12.3.3.2. Secondary Efficacy Analyses ..................................... 63
12.3.3.3. Other Analyses ........................................................... 65
12.3.4. Interim Analyses .......................................................................... 65
13.REFERENCES ....................................................................................................... 66
14.APPENDICES ........................................................................................................ 68
14.1. Appendix 1: Abbreviations and Trademarks ................................................ 68
14.2. Appendix 2: Study Governance Considerations .......................................... 70
14.3. Appendix 3: Adverse Events: Definitions an d Procedures for 
Recording, Evaluating, Follow -up, and Reporting ....................................... 74
14.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information .................................................................................................. 80
14.5. Appendix 5: Genetics .................................................................................. 83
14.6. Appendix 6: Liver Safety: Required Actions and F ollow -up 
Assessments .............................................................................................. 84
14.7. Appendix 7: AEs, ADEs, SAEs, SADEs, USADEs and Device 
Deficiencies: Definition and Procedures for Recording, Evaluating, 
Follow -up, and Reporting in Medical Device Studies .................................. 88
14.7.1. Definition of Medical Device AE and ADE .................................... 88
14.7.2. Definition of Medical Device SAE, SADE and USADE ................. 88
14.7.3. Definition of Device Deficiency ..................................................... 89
14.7.4. Recording and Follow -Up of AE and/or SAE and Device 
Deficiencies ................................................................................. 89
14.7.5. Reporting of SAEs ....................................................................... 91
14.7.6. Reporting of SADEs ..................................................................... 92
14.8. Appendix 8: Country -specific requi rements ................................................. 93
14.9. Appendix 9: COVID -19 Measures ............................................................... 94
14.10. Appendix 10: Prot ocol Amendment History ................................................. 98
2016N298634_04 CONFIDENTIA L
HZA107116
101. SYNOPSIS
Protocol Title: A randomised, double -blind, parallel group, multicentre, stratified, study  
evaluating the efficacy  and safet y of once dail y fluticasone furoate/vilanterol inhalation 
powder compared to once daily  fluticasone furoate inhalation powder in the treatment of 
asthma in participants aged 5 to 17 years old inclusive currentl y uncon trolled on inhaled 
corticosteroids
Short Title: A double- blind, parallel group study  to evaluate the efficacy and safet yof 
fluticasone furoate/vilanterol combination compared to fluticasone furoate in the 
treatment of asthma in participants ( aged 5 to 17 years old inclusive )
Rationale:
A variet y of asthma medications, generally targeting the inflammatory  and/or obstructive 
components of the disease, may  be selected for the treatment of asthma.  The 
evidence -based asthma treatment guidelines recommend a ste pwise approach to treat 
asthma where medications are increased or decreased when appropriate to gain and 
maintain disease control.  For patients with persistent asthma sy mptoms, the preferred 
initiating controller medication (step 2 in the step -wise treatm ent paradigm) is low -dose 
inhaled corticosteroid (ICS) to target the inflammatory  process in asthmatic airway s.  For 
children ≥5 y ears of age and adolescents on low -dose I CS whose asthma is uncontrolled, 
low-dose ICS plus adjunctive therap y (e.g. long -acting beta agonist [L ABA], leukotriene 
receptor antagonist [L TRA], theophy lline) or monotherapy  with medium -dose I CS, may  
all be considered as step 3 care . Due to the lack of comparative data for children ages 5 to 
11 years, the step 3 care options are considered equivalent. This study  will evaluate the 
efficacy  and safet y of fluticasone furoate/vilanterol (FF/V I) compared to fluticasone 
furoate (FF) in the treatment of asthma in children aged 5 to 17 y ears old inclusive .
FF/VI has not been approved in the US in the adolescent population (12 to 17years olds ) 
and as a result, a cohort of adolescents isincluded in this study  to further assess efficacy
and safet yin this population.
Objectives and Endpoints:
Objective Endpoint
Primary
Common to both 5-11 and 
5-17 years population
To compare the efficacy 
of once daily fluticasone 
FF/VI with once daily FF 
in participants with 
asthma .
The primary estimand is 
that of treatment policy Primary endpoint for  5 -11 
years population
Change from baseline, 
averaged over weeks 1 -
12 of the treatment 
period, in pre -dose (i.e. 
trough) morning peak 
expiratory flow (PEF), 
captured dail y via 
electronic patient diary Primary endpoint for 5 -17 
years population
Weighted mean FEV 1
(0-4 hours) at week 12.
This is the primary 
endpoint for the 5 -17y 
population [required by 
FDA]. This is a 
secondary endpoint for 
2016N298634_04 CONFIDENTIA L
HZA107116
11Objective Endpoint
(effectiveness -type 
estimand). The 
secondary efficacy -type 
estimand will be defined 
for the primary and 
powered secondary 
endpoints.This is the primary 
endpoint for the 5 -11y 
population [required by 
EMA]. This is a 
secondary endpoint for 
the 5 -17 years 
population.   the 5 -11 years 
population .
Secondary endpoints common to both 5 -11 and 5 -17 years 
population:
Change from baseline in the percentage of rescue -free 24 -
hour periods over weeks 1 -12 of the treatment period 
(powered secondary endpoint for 5-11 years population) 
captured daily via electronic patient diary.
Change from baseline in the percentage of symptom -free 
24-hour periods over weeks 1 -12 o f the treatment period, 
captured daily via electronic patient diary.
Change from baseline in morning (AM) forced expiratory 
flow in 1 second (FEV 1) in participants who can perform the 
manoeuvre at week 12.
Change from baseline in Asthma Control Questionnai re 
(ACQ -5) at week 24.
Incidence of exacerbations over the 24 week treatment 
period.
Other endpoints common to both 5- 11 and 5 -17 years 
population:
Change from baseline, averaged over weeks 1 -12 of the 
treatment period in evening (PM) PEF, captured daily via 
electronic patient diary.
Secondary
Common to both 5 -11 and 
5-17 years population
To assess the safety of 
FF/VI in participants with 
asthma Incidence of adverse events (AEs).
Evaluation of electrocardiogram (ECG) at screening and end 
of treatment.
Evaluation of fasting blood glucose pre -and post -treatment.
2016N298634_04 CONFIDENTIA L
HZA107116
12Overall Design:
This is a randomised, double -blind, parallel group, multicentre, stratified, study  designed 
to evaluate the efficacy  and safet y of once dail y FF/VI inhalation powder compared to
once dail y FF inhalation powder in the treatment of asthma in participants aged 5 to 17
years inclusive currentl y uncontrolled on inhaled corticosteroids.  The stud y will be 
conducted over approximately  29weeks.
Number of Participant s:
Approximately  2900 participants will be screened to achieve a total of 870 randomised
participants aged 5 to 17 y ears old inclusive .  Of this, 652 participants will be aged 5 to 
11 years ( and at least 163 (25%) must be aged 5 to less than 8 years), and 218 
participants will be aged 12 to 17 y earsinclusive .
Treatment Groups and Duration:
After completing a 4 -week open- label run -in period (during which all subjects will 
receive fluticasone propionate ( FP) 100 mcg twice daily ), eligible subjects, who me et
inclusion criteria fo r randomis ation will be stratified by their ageat the screening visit (5 
to 11 and 12 to 17) and randomised into a 24 week double -blind treatment period 
followed b y a 1 week follow -up period.
Subjects aged 5 -11 years of age will be randomised in a 1: 1 ratio to one of the following 
two treatments:
FF 50 mcg once daily
FF/V I 50/25 mcg once daily 
Subjects aged 12- 17 years of age inclusive will be randomised in a 1:1 ratio to one of the 
following two treatments:
FF 100 mcg once daily
FF/V I 100/25 mcg once daily
2016N298634_04 CONFIDENTIA L
HZA107116
132. SCHEDULE OF ACTIVITI ES (SOA )
The schedule of activities (SOA) in Table 1 details timing of procedures / assessments to 
be performed in this stud y.
The timing and number of planned study  assessments may  be altered during the course of 
the study  based on newl y available data to ensure appropriate monitoring. 
Any changes in the timing or addition of time points for any  planned stud y assessments 
must be documented and approved b y the relevant study team member and then archived 
in the sponsor and site study  files , but will not constitute a protocol amendment.  The 
institutional review board (I RB)/independent ethics committee (IEC) will be informed of 
any safet y issues that require alteration of the safety  monitoring scheme or amendment of 
the informed consent form (I CF).
2016N298634_04 CONFIDENTIA L
HZA107116
14Table 1 S chedule of Activities
Procedure Screening Pre-
randomisationRandomisation Treatment Period (Days, Weeks) ETD EW FU TC
(7 days 
post -last 
visit)
Visit V11
-4 to Day 
0V2 V3 V4 V5 V615 V7 V8 V9 V10
Week 0 4 82 12 162 203 24 25
Day
(All visits except V2 
to occur within - 5 to 
+2 days of specified 
day)-28 -5 (-2 to +2)
0 28 56 84 112 140 168 175
Type of VisitClinic 
onlyHome or 
Clinic
Clinic onlyHome 
or 
ClinicHome2, 
Video-
call or 
ClinicClinic 
onlyVideo-
call or 
clinicVideo -
call, 
Phone -
call or 
clinicHome 
or 
ClinicHome 
or 
ClinicHome 
or 
ClinicVideo- call, 
Phone -call 
Informed consent and 
assentX
Pharmacogenetics 
consent and assent=========================== 
Inclusion and 
exclusion criteriaX13
Randomisation criteria X
Demography X
Medical history X
Asthma history X
Exacerbation history X
2016N298634_04 CONFIDENTIA L
HZA107116
15Procedure Screening Pre-
randomisationRandomisation Treatment Period (Days, Weeks) ETD EW FU TC
(7 days 
post -last 
visit)
Visit V11
-4 to Day 
0V2 V3 V4 V5 V615 V7 V8 V9 V10
Week 0 4 82 12 162 203 24 25
Day
(All visits except V2 
to occur within - 5 to 
+2 days of specified 
day)-28 -5 (-2 to +2)
0 28 56 84 112 140 168 175
Type of VisitClinic 
onlyHome or 
Clinic
Clinic onlyHome 
or 
ClinicHome2, 
Video-
call or 
ClinicClinic 
onlyVideo-
call or 
clinicVideo -
call, 
Phone -
call or 
clinicHome 
or 
ClinicHome 
or 
ClinicHome 
or 
ClinicVideo- call, 
Phone -call 
Full physical exam 
including, height and 
weightX
EFFICACY ASSESSMENTS
Electronic patient diary 
4================================== X X
FEV 1 X X X X2 X X X5
FEV 1review of the 
overread onlyX
Serial FEV 1 X
Lung function (FEV 1) 
reversibility testing6X
cACT/ACT X X
ACQ X X X
2016N298634_04 CONFIDENTIA L
HZA107116
16Procedure Screening Pre-
randomisationRandomisation Treatment Period (Days, Weeks) ETD EW FU TC
(7 days 
post -last 
visit)
Visit V11
-4 to Day 
0V2 V3 V4 V5 V615 V7 V8 V9 V10
Week 0 4 82 12 162 203 24 25
Day
(All visits except V2 
to occur within - 5 to 
+2 days of specified 
day)-28 -5 (-2 to +2)
0 28 56 84 112 140 168 175
Type of VisitClinic 
onlyHome or 
Clinic
Clinic onlyHome 
or 
ClinicHome2, 
Video-
call or 
ClinicClinic 
onlyVideo-
call or 
clinicVideo -
call, 
Phone -
call or 
clinicHome 
or 
ClinicHome 
or 
ClinicHome 
or 
ClinicVideo- call, 
Phone -call 
SAFETY ASSESSMENTS
Oropharyngeal 
examinationXX X X X7
Concomitant 
medication review2X======================== X X X
12-lead ECG14 X X X X8
Vital signs X
AE review2 ========================  X X X
SAE review2 X ========================  X X X
Exacerbation review2 ========================  X X X
LABORATORY ASSESSMENTS
Blood draw for fasting 
glucose9X X X X10
Pregnancy Test X X X X
2016N298634_04 CONFIDENTIA L
HZA107116
17Procedure Screening Pre-
randomisationRandomisation Treatment Period (Days, Weeks) ETD EW FU TC
(7 days 
post -last 
visit)
Visit V11
-4 to Day 
0V2 V3 V4 V5 V615 V7 V8 V9 V10
Week 0 4 82 12 162 203 24 25
Day
(All visits except V2 
to occur within - 5 to 
+2 days of specified 
day)-28 -5 (-2 to +2)
0 28 56 84 112 140 168 175
Type of VisitClinic 
onlyHome or 
Clinic
Clinic onlyHome 
or 
ClinicHome2, 
Video-
call or 
ClinicClinic 
onlyVideo-
call or 
clinicVideo -
call, 
Phone -
call or 
clinicHome 
or 
ClinicHome 
or 
ClinicHome 
or 
ClinicVideo- call, 
Phone -call 
Pharmacogenetic 
sample (saliva)11 X
STUDY TREATMENT
Dispense standardised 
FP run -in medicationX
Return FP run -in 
medication X
Dispense SABA 
rescue inhalerX
Return SABA rescue 
inhalerX X
2016N298634_04 CONFIDENTIA L
HZA107116
18Procedure Screening Pre-
randomisationRandomisation Treatment Period (Days, Weeks) ETD EW FU TC
(7 days 
post -last 
visit)
Visit V11
-4 to Day 
0V2 V3 V4 V5 V615 V7 V8 V9 V10
Week 0 4 82 12 162 203 24 25
Day
(All visits except V2 
to occur within - 5 to 
+2 days of specified 
day)-28 -5 (-2 to +2)
0 28 56 84 112 140 168 175
Type of VisitClinic 
onlyHome or 
Clinic
Clinic onlyHome 
or 
ClinicHome2, 
Video-
call or 
ClinicClinic 
onlyVideo-
call or 
clinicVideo -
call, 
Phone -
call or 
clinicHome 
or 
ClinicHome 
or 
ClinicHome 
or 
ClinicVideo- call, 
Phone -call 
Treatment assignment 
(randomisation) via 
IVRSX
Dispense double -blind 
study treatment via 
IVRS/IWRS16X X X X X12 X
Return double -blind 
study treatmentX X X X X X X X
Abbreviations: AE=adverse event; ACT=Asthma control test; cACT= Childhood asthma control test ; ACQ=Asthma Control Questionnaire; ECG=electrocardiogram; ETD=early 
treatment discontinuation; EW=early w ithdrawal; FEV 1=forced expiratory volume in 1 second; FP= fluticasone propionate ; FU=follow -up; IVRS=interactive Voice Response 
System/Interactive Web Response System; SABA= short -acting beta agonist; SAE=serious adverse event; TC=telephone call; V=Visit .
1. Prior to any study activities at Visit 1, including fasting for the blood glucos e test , written informed consent should be obtained from at least one 1 parent/care giver (legal guardian) 
and accompanying informed assent from the participant (where the participant is able to provide assent).
Participants who are unable to perform the pre-bronchodilator FEV 1manoeuvre for any reason or  do not provide at least 2 acceptable pre or post bronchodilator measurements
[not necessarily repeatable] at Visit 1 can, at the discretion of the investigator, attend the clinic once more after Visit 1 t o attempt to perform the pre-bronchodilator and post -
2016N298634_04 CONFIDENTIA L
HZA107116
19bronchodilator FEV 1manoeuvres. This should be within 14 days of Visit 1 .The 4 week run -in will start after eligibility is confirmed following the spirometry re -test. The window for 
Screening in this case will start at the re -test. 
2. Week 8 (Visit 5) and Week 16 (Visit 7 ) can be parent only visit or video -calls.   For these visits, parents may need to come to the site to collect and return any study medication if 
direct to patient IP shipment is not available for any reason. .  Parents should bring the diary to allow for review of concomitant medications, AEs, SAEs and exacerbations.    Note :  
If the participant does attend Visit 5 with the parent (or has a ho me-visit) andthe visit occurs during the morning (6.00am to 11.00am) then the spirometry measure should be
performed.  If only the parent attends the clinic , then the visit can be at any time of day.     
3. Week 20 (Visit 8 ) can be a telephone call if there are no prob lems with compliance.
4. Asthma symptom scores, peak expiratory flow (PEF) , rescue a lbuterol/salbutamol usage will be recorded on the electronic patient diary.  To be completed every day in the 
morning and evening from Visit 1 through to Visit 6only.  
5. FEV 1is not required at the Early Withdrawal Visit or Early Treatment Discontinuation V isit if these visits occurred after Visit 6.
6. Following administration of 2 to 4 inhalations of albuterol/salbutamol.  Reversibility testing includes a baseline spirometry and repeat spirometry within 15to40 minutes after 
inhalation of 400 µg of salbutamol/albuterol .  The reversibility test will be considered positive if participants show improvement of FEV1 ≥12%  after administration of 
salbutamol /albuterol .
7. Oropharygneal examination is n ot required at the Early Withdrawal Visit if examination was performed at Early Treatment Discontinuation Visit.
8. A 12-lead ECG is not required at the Early Withdrawal Visit if it was measured at the Early Treatment Discontinuation Visit.
9. A blood draw is not required at the Early Withdrawal Visit if it was collected at the Early Treatment Discontinuation Visit.
10. A central laboratory will be used.
11. Informed consent for optional substudies ,e.g.genetics consent must be obtained before collecting a sample.  Sample to be obtained post -randomisation.
12. Two inh alers to be dispensed at Visit 7 as Visi t 8does not need to be in the clinic if there are no problems with compliance .
13. Participants who provide an acceptable spirometry measure at screening but wh o do not meet the spirometry related inclusion criteria at this visit can be re -screened (see Section 
8.3).
14. Single or averaged QTc values of triplicate electrocardiograms to be obtained over a brief (e.g. 5 to 10 minute) recording pe riod – see Section 10.1.2 . 
15. If the participant is unable to attend the clinic at V6 for any reason, every attempt should be made to bring the participant back to the clinic to collect serial spirometry as soon as 
possible between Week 12 ( Visit 6) and Week 24 ( Visit 9 ). 
16. Study medication may be delivered directly to the participant, if the participant is not attending the clinic.
2016N298634_04 CONFIDENTIA L
HZA107116
203. INTRODUCTION
3.1. Stud y Rationale
A variet y of asthma medications, generally targeting the inflammatory  and/or obstructive 
components of the disease, may  be selected for the treatment of asthma.  The 
evidence -based asthma treatment guidelines recommend a stepwis e approach to treat 
asthma where medications are increased or decreased when appropriate to gain and 
maintain disease control.  For patients with persistent asthma sy mptoms, the preferred 
initiating controller medication (step 2 in the step -wise treatment paradigm) is low -dose 
ICS to target the inflammatory  process in asthmatic airway s.  For children ≥5 years of 
age and adolescents on low- dose ICS whose asthma is uncontrolled, low -dose I CS plus 
adjunctive therap y (e.g. long -acting beta agonist [LABA], leuko triene receptor antagonist 
[LTRA], theophy lline) or monotherapy  with medium -dose I CS, may  all be considered as 
step3 care (Global Initiative for Asthma [ GINA, 2016 ; National I nstitutes of Health NI H, 
2007 ).  Due to the lack of comparative data for children ages 5 to 11 years, the step 3 care 
options are considered equivalent. Fluticasone furoate/vilanterol ( FF/VI )has not been 
approved in the US in the adolescent population (12 to less than 18 y ears old) and as a 
result, a cohort of adolescents was included in this study  to assess further efficacy  and 
safet y in this population.
This study  will evaluate the efficacy  and safet y of fluticasone fur oate/vilanterol (FF/VI) 
compared to fluticasone furoate (FF) in the treatment of asthma.   These objectives are 
common to the two study populations of interest:  the 5- 11 years (inclusive) population 
and the 5- 17 years (inclusive) population.
The rational efor the study  design is provided in Section 7.1.
3.2. Background
Asthma is a chronic disease of the lungs characterized by  airway  inflammation, 
bronchoc onstriction and increased airway  responsiveness.  Corticosteroids are the 
cornerstone of anti -inflammatory  therapy  for persistent asthma.  The goal of asthma 
treatment is to achieve and maintain asthma control and to reduce the future risk of 
exacerbations .  ICSare considered the most effective anti- inflammatory  treatments for all 
severities of persistent asthma [GINA, 2016; NIH, 2007 ].  The benefits of ICS include 
control of asthma s ymptoms, improvement in lung functi on, decrease in airway  hyper-
responsiveness and possibly , prevention of airway wall remodelling [Pedersen, 1997; 
Fanta , 2009].
FF(GW685698) as the ICS component and vilanterol (VI; GW642444) as the L ABA 
component of the ICS/LABA combination, hereafter referred to as FF /VI, has been 
approved at the 100/25 mcg and 200/25 mcg dose in over 60 countries for once dail y 
treatment of asthma.  FF/VI 100/25 mcg is also indicated for the maintenance treatment 
of airflow obstruction in patients with chronic obstructive pulmonary  disease (COPD) 
including chronic bronchiti s and/or emphy sema and to reduce exacerbations of COPD in 
patients with a history  of exacerbation.
2016N298634_04 CONFIDENTIA L
HZA107116
21FF is approved in the United States of America and 10 other countries (Canada, 
Australia, Chile, Philippines, Switzerland, Singapore , New Zealand, South Kore a, 
Mexico and Japan) for use as a once dail y ICS for the maintenance treatment of asthma in 
patients aged 12 years and over. 
The FF and FF/VI paediatric asthma development programmes are currently  ongoing.
3.3. Benefit/Risk A ssessment
Summaries of findings fro m both clinical and non -clinical studies conducted with 
fluticasone furoate (FF) and fluticasone furoate/vilanterol (FF/VI) can be found in the FF 
and FF/VI Investigator’s Brochures ( GlaxoSmithKline Document Number: 
GM2004/00283/11, GlaxoSmithKline Document Number: RM2008/00012/09).
The following S ection outlines the risk assessment and mitigation strategy  for this 
protocol
3.3.1. Risk A ssessment FF and FF/ VI
For FF and FF/VI, the risks associated with inhaled corticosteroids (ICS) and long -acting 
beta 2agonists (LABA) as well as the miti gation strategy  applicable to adults and 
adolescent asthma patients are also considered applicable to paediatric patients with 
asthma.
The risks are referenced in the summary  of safety  concerns in the most recently  approved 
European Union Risk Mana gement P lan (EU -RMP) for FF/VI . 
The summary  of data/rationale for the risks are referenced from the most currentl y 
available development safety  update report (DSUR reporting period 03 July 2015 to 02 
July 2016) (doc ref number: 2016N278503) and from completed cli nical studies since 
July 2016.
Only  those risks considered of clinical significance with respect to the participants
included in this study  are provided.
Potential risk of Clinical 
significanceInvestigational product Summary of data/ 
Rationale for the riskMitigation strategy
Pneumonia FF and FF/VI Pneumonia is a risk 
carried by the inhaled 
corticosteroids class of 
compounds. An increase 
incidence of pneumonia 
with higher doses of ICS 
cannot be ruled out; 
however, the absolute risk 
of pneumonia with FF
appears to be very small 
and consistent with other 
ICS.The risk of pneumonia in 
asthma patients is very 
low and is consistent with 
the risk of other ICS. 
Subjects are alerted to the 
potential risk of 
pneumonia in the informed 
consent. Investigators are 
informed of the risk in 
Section 6 Warnings and 
Precautions S ection of the 
IB. Subjects with 
concurrent respiratory 
2016N298634_04 CONFIDENTIA L
HZA107116
22Potential risk of Clinical 
significanceInvestigational product Summary of data/ 
Rationale for the riskMitigation strategy
For FF; in an integrated 
analysis of 10 studies in 
asthma (6219 patients) 
the incidence of 
pneumonia seen with FF 
100 (8.5/1000 patient 
years) was similar to 
placebo (10.8/1000 
patient years) and slightly 
higher with FF 200 
(23.6/1000 patient years).  
Few of the pneumonia 
events were serious and a 
similar incidence was 
observed across all 
treatment groups.  
An increase incidence of 
pneumonia with higher 
doses of ICS cannot be 
ruled out; however, the 
absolute risk of 
pneumonia with FF 
appears to be very small 
and consistent with other 
ICS.
For FF/VI:
In an integrated analysis 
of 18 studies in asthma 
(10,322 patients), the 
incidence of pneumonia 
(adjusted for exposure, 
due to low numbers and 
limited num ber of patients 
on placebo) seen with 
FF/VI 100/25 mcg 
strength (8.5/1000 patient 
years) was similar to 
placebo (9.3/1000 patient 
years). There was a 
higher incidence of 
pneumonia in the FF/VI 
200/25 mcg strength 
(18.3/1000 patient years) 
compared to the F F/VI 
100/25 microgram 
strength. Few of the 
pneumonia events led to 
hospitalisation with either 
strength, and there were 
no observed differences in 
the incidence of serious disease are excluded from 
the study.
2016N298634_04 CONFIDENTIA L
HZA107116
23Potential risk of Clinical 
significanceInvestigational product Summary of data/ 
Rationale for the riskMitigation strategy
events between the two 
treatment strengths.
Hypersensitivity FF and FF/VI For FF and FF/VI there 
were few events reported 
in the asthma studies.  As 
there was limited, short, 
exposure to placebo, any 
comparison is not reliable.
Spontaneous reports 
consistent with 
hypersensitivity reactions 
to inhaled FF/VI were 
identified on the GSK 
safety database.Subjects and their 
parents/guardians will be 
informed about the risk of 
hypersensi tivity in the 
informed consent. They 
will be advised to seek 
medical treatment if any 
signs/symptoms of 
hypersensitivity occur. 
Subjects with milk protein 
allergy or known 
hypersensitivity to FF, the 
class of ICS or any 
ingredient of the IP 
preparation wil l be 
excluded from 
participating in the study. 
Investigators are informed 
of this in Section 6 (contra -
indications) of the IB.
Systemic corticosteroid 
effects (adrenal 
suppression, effects on 
the eye, growth 
retardation)FF and FF/VI These are class risk s
carried by all inhaled 
corticosteroid products.
Adrenal suppression
No studies have shown a 
clinically relevant effect of 
FF/VI on the hypothalamic 
pituitary axis (HPA). This 
includes a formal HPA 
study (HZA106851), using 
24 hour serum cortisol 
measurements, and 
multiple studies with 
COPD and asthma 
subjects which monitored 
urinary cortisol.
A completed 6-week HPA 
axis study in children aged 
5 to 11 years old did not 
show a clinically relevant 
effect of FF 50 mcg OD on 
adrenal function assessed 
by 24-hour serum cortisol 
profiles (HZA107118).Subjects and their parents/ 
guardians will be informed 
about the risks in the 
informed consent. 
Investigators are made 
aware of the potential for 
these class effects in 
Section 6 (warnings and 
precautions) of the IB. 
2016N298634_04 CONFIDENTIA L
HZA107116
24Potential risk of Clinical 
significanceInvestigational product Summary of data/ 
Rationale for the riskMitigation strategy
Corticosteroid -associated 
ocular effects
In study HZA106839 
(FF/VI and FP in subjects 
with asthma), formal 
Ophthalmic assessments 
were conducted (including 
lens opacities 
classification system 
[LOCS ]III evalu ations for 
ocular opacities) 
throughout the study. This 
study showed no apparent 
effects on lens 
opacification, compared to 
baseline. 
During studies in both 
subjects with asthma and 
COPD, no associated 
effect on ocular disorders 
was observed.
Growth retar dation
Children with asthma may 
experience growth 
retardation, which has 
been attributed to the 
delayed onset of puberty 
seen in asthmat ics relative 
to non -asthmatics [ GINA , 
2016).  A systematic 
review of 25 trials 
involving 8471 (5128 ICS -
treated and 3343 control) 
children with mild to 
moderate persistent 
asthma showed that 
regular use of ICS at low 
or medium daily doses 
was associated with a 
statistically significant 
reduction in linear growth 
velocity (14 trials including 
5717 participants; MD -
0.48 cm/y, 9 5% 
confidence interval (CI) -
0.65 to -0.30, P value 
<0.0001) and in change 
from baseline in height (15 
trials including 3275 
participants; MD- 0.61 
2016N298634_04 CONFIDENTIA L
HZA107116
25Potential risk of Clinical 
significanceInvestigational product Summary of data/ 
Rationale for the riskMitigation strategy
cm/y, 95% CI -0.83 to 
-0.38, p value < 0.00001) 
during a one -year 
treatment period. The 
effect size of ICS on linear 
growth velocity appeared 
to be associated more 
strongly with the ICS 
molecule than with the 
device or dose.  ICS -
induced growth 
suppression seemed to be 
maximal during the first 
year of therapy and less 
pronounced during 
subsequent years of 
treatment. This review did 
not find an overall effect of 
ICS during the first three 
months of treatment 
[Zhang, 2014].  A recent 
study demonstrated a 
reduced mean adult 
height of 1.2cm (95% CI: -
1.9 to 
-0.5) in subjects who 
received inhaled 
budesonide compared to 
placebo, af ter use of 4 to 
6 years [ Kelly , 2012].
A completed knemomet ry 
study did not show a 
clinically significant effect 
of FF on short term leg 
growth compared with 
placebo (HZA107112).
Serious asthma related 
eventsFF/VI This is a risk carried by 
the class of LABA 
compounds.
During the FF/VI studies 
for the asthma composite 
endpoint (asthma 
exacerbations leading to 
hospitalization, intubation 
and/or death), there was 
no significant difference 
between the FF/VI group 
and the ICS group or non -
LABA group, 
demonstrating no 
increased risk when 
adding a LABA to an ICS.Subjects with history of 
life-threatening asthma are 
excluded from the study. 
Inclusion criteria for the 
study require a subject to 
have their asthma disease 
controlled by current 
therapy. Subjects 
complete daily electronic 
diary entries for the 
symptoms of asthma, 
peak expiratory flow ( PEF)
and rescue medication 
use. Subjects will be 
advised to contact the 
2016N298634_04 CONFIDENTIA L
HZA107116
26Potential risk of Clinical 
significanceInvestigational product Summary of data/ 
Rationale for the riskMitigation strategy
Three large completed 
studies with ICS/LABA 
compounds (one in 
paediatric subjects) have 
shown no increased risk 
of serious asthma related 
even ts compared with ICS 
alone [ Stempel , 2016a; 
Stempel , 2016b; Peters , 
2016].investigator or their 
physician immediately.
3.3.2. Benefit A ssessment
Inhaled corticosteroids (ICS)
The use of ICS is well established in international treatment guidelines for paediatric 
asthma patients [ GIN A , 2016] . The benefits of an I CS include control of asthma 
symptoms, improvement in lung function and a decrease in airway  hyperresponsiveness. 
In addition subjects will receive SABA for use as needed for relief of asthma sy mptoms. 
Additio n of LABA to ICS
Combined treatment with ICS and LABA has been shown to be more effective than the 
individual components in asthma, leading to the development of fixed dose combination 
inhalers. The use of ICS/LABA is now well established in international treatment 
guidelines for patients for whom treatment with an I CS alo ne is no longer sufficient.
Improved compliance with once -daily  treatment regimen
Data with marketed products suggests that compliance improves with less frequent 
administration and, therefore, it is expected that a once- daily treatment will improve 
compliance, which may  lead to improvements in disease control and reductions in 
healthca re resource utilisation costs [ Price , 2010; Toy , 2011; Wells , 2013].
3.3.3. Overall Benefit:Risk Conclusion
GSK has assessed this study  for any  potential risks that a subject may  experience. The 
investigational products (FF and FF/ VI) have acceptable safet y profiles for clinical use. 
The risks documented for FF and FF/VI belong to the class of products to which FF and 
FF/V I belong. The data support a positive benefit risk balance for the product. This 
conclusion is supported by the results of previously  conducted clinical studies with the 
products in health y volunteers and subjects with asthma and COPD. A safety criterion 
outlining details for subject discontinuation from IP or earl y withdrawal is included in the 
protocol (Section 10). Routine safet y analyses of adverse events (AEs) and serious 
adverse events (SAEs) from this study  will be conducted by  GSK.
2016N298634_04 CONFIDENTIA L
HZA107116
27Taking into account the measures to minimise risk to subjects participating in this study , 
the potential risks identified in association with FF and FF/VI are justified by  the 
anticipated benefits that may be afforded to paediatric patients with asthma.
For the FP/Salmeterol section, information is taken from the current approved product 
information of Advair. Since Advair contains an ICS and L ABA, the risk mitigation 
strategies for FF (ICS) and VI (LABA) component will be applicable .
4. OBJECTIVES A ND ENDPO INTS
Objective Endpoi nt
Primary
Common to both 5 -11 and 
5-17 years population
To compare the efficacy 
of once daily fluticasone 
FF/VI with once daily FF 
in participants with 
asthma.
The primary estimand is 
that of treatment policy 
(effectiveness-type 
estimand).  The 
secondary efficacy -type 
estimand will be defined 
for the primary and 
powered secondary 
endpointsPrimary endpoint for  5 -11 
years population
Change from baseline, 
averaged over weeks 1 -
12 of the treatment 
period, in pre -dose (i.e. 
trough) morning peak 
expiratory flow (PEF), 
captured daily via 
electronic patient diary. 
This is the primary 
endpoint for the 5 -11y 
population [required by 
EMA]. This is a 
secondary endpoint for 
the 5 -17 years 
population.   Primary endpoint for 5 -17 
years population
Weighted mean FEV1 
(0-4 hours) at week 12.  
This is the primary 
endpoint for the 5 -17y 
population [required by 
FDA]. This is a 
secondary endpoint for 
the 5 -11 years 
population.
Secondary endpoints common to both 5 -11 and 5 -17 years 
population:
Change from baseline in the percentage of rescue -free 24 -
hour periods over weeks 1 -12 of the treatment period 
(powered secondary endpoint for 5-11 years population) 
captured daily via electronic patient diary.
Change from baseline in the percentage of symptom -free 
24-hour periods over weeks 1 -12 of the treatment period, 
captured daily via electronic patient diary.
Change from baseline in morning (AM) forced expiratory 
flow in 1 second (FEV 1) in participants who can perform the 
manoeuvre at week 12.
2016N298634_04 CONFIDENTIA L
HZA107116
28Objective Endpoi nt
Change from ba seline in ACQ -5 at week 24.
Incidence of exacerbations over the 24 week treatment 
period.
Other endpoints common to both 5- 11 and 5 -17 years 
population:
Change from baseline, averaged over weeks 1 -12 of the 
treatment period in evening (PM) PEF, captured daily via 
electronic patient diary. 
Secondary
Common to both 5 -11 and 
5-17 years population
To assess the safety of 
FF/VI in participants with 
asthma Incidence of adverse events (AEs).
Evaluation of fasting blood glucose pre -and post -treatment.
5. STUDY DESIGN
5.1. Overall Design
This is a randomi sed, double -blind, stratified, parallel group, multicentre study  evaluating 
the efficacy  and safety  of once dail yFF/VI inhalation powder compared to once dail y FF
inhalation powder in the treatment of asthma in participants aged 5 to 17 y ears old 
inclusive currentl y uncontrolled on inhaled corticosteroids. The overall study design is 
shown in Figure 1.
2016N298634_04 CONFIDENTIA L
HZA107116
29Figure 1 Study  Schematic
This study  will be conducted over a total duration of approximately  29 weeks: 4 week 
run-in period, 24- week double -blind treatment period and 1 -week follow -up period.  
Participants who meet the eligibility  criteria at Visit 1 (or after spirometry re-test) will 
enter a 4 week open -label run-in period.  D uring the 4 week run -in period, all subjects 
will receive fluticasone propionate (FP) 100mcg twice dail y.   
After completing the run-in per iod, eligible participants will be stratified b y age (5 to 11 
and 12 to 17) and randomis ed into a 24 wee k double -blind treatment period, as follows:
Participants aged 5 to11 years of age will be randomis ed in a 1: 1 ratio to one of the 
following two treatments:
FF 50 mcg once daily in the morning
FF/V I 50/25 mcg once daily in the morning
Participants aged 12 to 1 7 yearsof age will be randomised in a 1:1 ratio to one of the 
following two treatments:
FF 100 mcg once daily in the morning
FF/V I 100/25 mcg once daily in the morning
Each treatment will be administered via the ELLIPTA dry powder inhaler (formerl y 
referred to as a Novel Dry  Powder Inhaler [NDPI ]).
Visit 1
-
4 Wk
4 week run
 -
in 
on FP
R
FF 50 OD
(n = 326)
FF/VI 50/25 OD
(n = 326)
FF/VI 100/25 OD
(n = 109)
Visit 3 
Day 0
FF 100 OD
(n = 109)
adolescents
paediatrics
Visit 6
Week 12
Visit 9
Week 24
Visit 4 
Week4
Visit 5 
Week 8
Visit 7 
Week 16
Visit 8
Week 20
FU TC
Week 25
Visit 2 
Visit 1 and 3 must be done in the clinic. Spirometry for V6 must be done in the clinic. Visit 2 is for spirometry only and 
can be at home or clinic. Visit 5 and Visit 7 can be parent only visits or video -calls. If spirometry is done at Visit it 5, it 
can b e done at home or clinic. Visit 4, 9, ETD and EW can be done in the home or clinic. Visit 8 can be a video -call, 
phone- call or clinic visit. The FU TC can be a phone -call or video -call.  
–;-
2016N298634_04 CONFIDENTIA L
HZA107116
30In addition, each participant will receive a short acting beta 2 agonist (SABA) (i.e., 
albuterol/salbutamol [inhalation aerosol or nebuliser]) to be used as needed throughout 
the entire stud y period as rescue medicati on for s ymptomatic relief of asthma symptoms.
Participants are required to attend the clinic at Visits 1, 3 and6.. . Visit 2 is for 
spirometry  only and can be at home or in the clinic. Visit 5 and Visit 7 can be parent onl y 
visits or video- calls. If spirometry  is done at Visit it 5, it can be done at home or in the 
clinic. Visit 4, Visit 9, ETD and EW can be done in th e home or clinic. Visit 8 can be a 
video- call, phone -call or clinic visit. The FU TC can be a phone- call or video- call. All 
spirometry  (in the clinic or at home) must be started between 6am and 11am. 
6. NUM BER OF PA RTICIPA NTS
Approximately  2900 participants will be screened to achieve a total of 870 randomised
participants aged 5 to 17 years, inclusive.  Of this, 652 participants will be aged 5 to 11 
years (and at least 163 (25%) must be aged 5 to less than 8 y ears), and 218 participants 
will be aged 12 to 1 7 years inclusive.
A 70% screening failure rate is expected.
7. PARTICIPA NT AND STUD Y COMPLETION
A participant is considered to have completed the study  if he/she has completed all visits 
of the study  including the follow -up phone contact as shown in the S OA (Section 2).
A subject will be considered discontinued from study  treatment if the subject was 
randomised, but intentionally  and permanently  stopped taking study  treatment during the 
treatment period.
A subject will be considered withdrawn from the study  if the subject left the study  prior 
to completing all required visits and the follow -up phone contact.
The end of the stud y is defined as the date of the last visit o f the last participant in the 
study  or last scheduled procedure shown in the S OA.
7.1. Scientific Rationale for Study  Design
The design of this study  has been developed based on advice received from the Food and 
Drugs Administration (FDA) and the European Medicines Agency  (EMA) Scientific 
Advice Working Party  (SAWP) and subsequently  agreed with the Paediatric Committee 
(PDCO )via a modification to the paediatric investigational plan ( PIP).
This study  is designed to evaluate the efficacy  and safet y of FF/VI in participant s aged 5 
to 11 y ears old with asthma currently  uncontrolled on I CS.  In addition, the study  is 
designed to evaluate the efficacy  and safet y of FF/VI  in participants aged 5 to 17 y ears 
old with asthma that areuncontrolled on I CS.  The dose will be FF/VI 50/25 mcg for 
participants aged 5 to 11 years old and FF/VI 100/25 mcg for participants aged 12 to 17 
2016N298634_04 CONFIDENTIA L
HZA107116
31years old.  For each population (5 -11 years and 5 -17 years), the study  is designed to show 
a statistically  significant difference bet ween FF/VI (ICS/ LABA combination therap y) 
and FF alone (ICS monotherap y),thereby  demonstrating the contribution of the L ABA 
(VI).   
The treatment duration of the study is 24 weeks, which is considered to be sufficient to 
evaluate safet y.  Twelve weeks of treatment is considered to be sufficient to demonstrate 
efficacy  in the proposed study  population.
7.2. Dose Justification
The safet y and efficacy  of a fixed -dose combination of FF 50 mcg and VI 25 mcg in 
asthmatic children aged 5 to 11 years of age (inclusive) will be evaluated in this study . 
This will be compared to a dose of FF 50 mcg alone. The doses of each of the 
components of FF/VI were selected from the results of two Phase IIb studies dose 
ranging studies HZA106853 for VI and HZA106855 for FF in asthmatic participant s 
aged 5 to 11 years of age (inclusive).
HZA106853 was a dose -ranging stud y that eva luated 3 doses of VI (6.25 to 25 mcg on a 
background of ICS) over a 4 -week treatment period in children aged 5 to 11 years,who 
were s ymptomatic on a low -dose ICS. Taking the totality  of the data, lung function and 
symptoms, into consideration, a 25 mcg dose of VI was considered the most appropriate 
to take forward into combination with FF in this study .
HZA106855 was a dose ranging stud y that evaluated 3 doses of FF (25 t o 100 mcg) over 
12weeks of treatment in children aged 5 to 11 years with asthma who were sy mptomatic 
on a SABA, LTRA or low -dose ICS.  Taking the totality  of data into consideration, 
50mcg has been selected as the appropriate dose to take forward into combination with 
VI in this study .
In subjects aged 12 to17 years of age FF 100mcg has been selected for this study  as this 
is the starting dose currently  approved for FF in subjects aged 12 years of age and older.  
FF/V I 100/25 mcg has been selected as the appropriate dose in this study  for this age 
group based on the data generated from the FF and VI Phase IIb and FF/VI Phase III 
studies in subjects aged 12 y ears and older.  FF/VI 100/25 is the approved start ing dose in 
over 60 countries for the once dail y treatment of asthma .
8. STUDY POPULA TION
Prospective approval of protocol deviations to recruitment and enrolment criteria, also 
known as protocol waivers or exemptions, is not permitted.
8.1. Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria 
apply at Visit 1:
2016N298634_04 CONFIDENTIA L
HZA107116
32Age
1.Between 5 and 17 years of age inclusive, at the time of screening .
Type of Participant and Disease Characteristics
2.A history  of symptoms consistent with a diagnosis of asthma for at least 6 months.
3.Pre-bronchodilator FEV 1>50% to ≤100% predicted normal. A minimum of 2 efforts 
that are considered acceptable (not necessaril y repeatable) are required to be eligible 
(see Section 11.1.1 ).
NOTE:  These FEV 1measurements must be acceptable and must meet the FEV 1
inclusion limits (as stated above) and the reversibility  requirem ents (below) to be 
eligible for the study . Participants who are unable to perform the pre-bronchodilator 
FEV 1manoeuvre for any reason or do not provide at least 2 acceptable pre or post 
bronchodilator measurements [not necessarily repeatable] at Visit 1 can, at the 
discretion of the investigator, attend the clinic once more after Visit 1 to attempt to 
perform the pre -bronchodilator and post -bronchodilator FEV 1manoeuvres. This 
should be within 14 days of Visit 1 Patients who provide an acceptable 
spiromet ry measure, but who do not meet the spirometry related criteria 
(Inclusion criteria 3 and 4) are considered screen failures but can be re -screened 
(see Section 8.3).  
4.Lung function reversibility  defined as an increase of ≥12% in FEV 1within 1 5 to 
40minutes following 2 to 4 inhalations of albuterol/ salbutamol inhalation aerosol (or 
1 nebulised treatment with albuterol/salbutamol solution).  Use of a spacer is 
permitted.
NOTE:  Participants who meet inclusion criteria 3 with a technicall y acceptable pre -
bronchodilator FEV 1manoeuvre at Visit 1 , but are then unable to perform the 
technicall y acceptable post -bronchodilator FEV 1needed for reversibility  can, at the 
discretion of the investigator, attend the clinic once more after Visit 1 to attempt to 
perform both the pre -bronchodilator and post- bronchodilator FEV 1manoeuvres 
again.  This should be within 14 days of Visit 1. These FEV 1measurements must be 
acceptable and must meet the FEV 1inclusion limits and the reversibility  requirements 
to be eligible for the study .  Patients who provide an acceptable spirometry 
measure, but who do not meet the spirome try related criteria (3 and 4) can be 
re-screened (see S ection 8.3).  
5.Uncontrolled asthma, with a cACT /ACT score ≤19.
6.Receiving stable asthma therap y (SABA or SAMA inhaler plus ICS [ total daily  dose 
≤FP 250 mcg or equivalent] )for at least 4 weeks prior to Visit 1(i.e., screening) .
7.Able to replace their current SABA /SAMA treatment with salbutamol /albuterol
aerosol inhaler at Visit 1 for use as n eeded for the duration of the study . 
Salbutamol /albuterol metered dose inhaler (MDI) will be administered with or 
without a spacer, to be used as determined b y the investigator. The use or non- use of 
the spacer should be consistent for an individual participant throughout the study .
2016N298634_04 CONFIDENTIA L
HZA107116
33Sex
8.Male or female participants
Females of reproductive potential must agree to follow 1 of the options listed (which 
include abstinence) in the Modified L ist of Highly  Effective Methods for Avoiding 
Pregnancy  in Females of Reproductive Potential (FRP) (see Section 14.4) from 
30days prior to the first dose of study  medication and until at least five terminal 
half-lives OR until any  continuing pharmacologic effect has ended, whichever is 
longer after the last dose of study  medication and completion of the follow -up call . 
The investigator is responsible for ensuring that participant s understand how to 
properl y use these methods of contraception.
Note:   Any female participant who is lactating (breastfeeding) will notbe included 
in the st udy.
Informed Consent
9. Written informed consent from at least 1 parent/care giver (legal guardian) and 
accompan ying informed assent from the participant (where the participant is able to 
provide assent) prior to admission to the study . 
If applicable, participant must be able and willing to give assent to take part 
in the study  according to the local requirement. The study  investigator is 
accountable for determining a child's capacity  to assent to participation in a 
research stud y, taking into consider ation an y standards set b y the responsible 
IEC.
Participant and their legal guardian(s) understand that the study  requires them 
to be treated on an outpatient basis.
Participant and their legal guardian(s) understand that they  must compl y with 
study  medica tion and study  assessments including recording of PEF and 
rescue SABA use, attending scheduled study  visits, and being accessible by  a 
telephone call.
8.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medic al Conditions
1.A history  of life threatening asthma defined for this protocol as an asthma episode 
that required intubation and/or was associated with hy percapnea, respiratory  arrest or 
hypoxic seizures.
2.Any asthma ex acerbation requiring the use of oral steroids within 6 weeks of Visit 1, 
systemic or depot corticosteroids within 12 weeks of Visit 1, OR ER attendance 
within 3 months of Visit 1 OR hospitalisation within 6 months of Visit 1.   
2016N298634_04 CONFIDENTIA L
HZA107116
343.A culture documented or suspected bacterial or viral infection of t he upper or lower 
respiratory  tract, sinus or middle ear that has not r esolved within 4 weeks of Visit 1 
and which led to a change in asthma management or, in the opinion of the 
investigator, is expected to affect the participant ’s asthma status or the participant ’s 
ability  to participate in the study .
4.Clinical visual evidence of orophary ngeal candidiasis.
5. Fasting blood glucose at screening >100 mg/dl (5.6m mol/L) .  NOTE:  Participants 
who have a value that is above >100 mg/dl can have a repeat test befor e Visit 2 .  
6.Severe o besit y (BMI above the 99th centile based on the CDC charts).
7.Any significant abnormality  or medical condition identified at the screening medical 
assessment (including serious psy chological disorder) that in the investigator’s 
opinion, preclude entry  into the study  due to risk to the participant or that may  
interfere with the conduct and/or outcome of the study .
8.QT interval corrected using Fridericia’s formula (QTcF) >450 msec or QTc F>480 
msec in participant s with bundle branch block or any  other clinicall y significant 
abnormality  in the Screening 12 -lead ECG.
Notes: 
For purposes of data analy sis, QT interval corrected for heart rate according to 
Bazett’s formula ( QTcB ), Fridericia’s formula ( QTcF ), another QT correction 
formula, or a composite of available values of QTc will be used as specified in the 
Reporting and Anal ysis Plan (RAP).
Prior/Concomitant Therapy
9.Use of an y prohibited medications listed in Section 9.7.1 .
Relevant Habits
10.Present use of any tobacco products including e -cigarettes and vaping .
Contraindications
11.Drug allergies: an y adverse reaction including immediate or delay ed hy persensitivity  
to any  beta 2-agonists, s ympathomimetic drug or any  intranasal, inhaled, or sy stemic 
corticosteroid therap y. Known or suspected sensitivity  to the constituents of the 
ELLIPTA Inhaler (i.e. l actose or magnesium stearate).
12.Milk Protein Allergy : history  of severe milk protein allergy .
Diagnostic Assessments and Other Criteria
13.Participated in a clinical trial and has received an investigational product within the 
following time period prior to th e first dosing day  in the current study : 30 day s, five 
half-lives or twice the duration of the biological effect of the study  treatment
(whichever is longer).
14. Exposure to more than 4 investigation al medicinal products within 12 months prior to 
the first do sing day .
2016N298634_04 CONFIDENTIA L
HZA107116
3515.An affiliation with the investigator site: the parents/guardians or child is an immediate 
family  member of the p articipating investigator, sub -investigator, stud y coordinator, 
oremploy ee of the participating i nvestigator.
16.The parent or g uardian has a history  of ps ychiatric disease, intellectual deficiency, 
substance abuse or other condition (e.g. inability  to read, comprehend or write) which 
may affect:
validity  of consent to participate in the study
adequate supervision of the participant during the study
compliance of participant with study  medication and study  procedures 
(e.g. completion of dail y diary , attending scheduled clinic visits)
participant safety  and well- being
17. Children in care:  children who are wards of the government or state are not eligible 
for participation in this study .
8.3. Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  
but are not subsequentl y randomis ed in the study . A minimal set of screen failure 
information is req uired to ensure transparent reporting of screen failure participants to 
meet the Consolidated Standards of Reporting Trials (CONSORT) publishing 
requirements and to respond to queries from regulatory  authorities. Minimal information 
includes demograph y, screen failure details, eligibility  criteria, and any  serious adverse 
events (SAE s).
Participants who fail an y of the screening or run -in criteria for any  reason may be re -
screened once after a period of at least 1 month from the date of screen failure or r un-in 
failure.   
Any re-screened subject must satisfy  all of the protocol specified inclusion/exclusion 
requirements at the re -screening visit. Re -screened subjects should be assigned a new 
subject number at the time of re -screening.
8.4. Randomisation Criteria
Subjects must meet the following criteria to be eligible for randomisation:
8.4.1. Inclusion Criteria for Randomis ation to Treatment
1.Asthma control: uncontrolled asthma, with a cACT /ACT score ≤19.
2.A technicall y acceptable pre -bronchodilator FEV 1>50% to ≤100% predicted normal
at Visit 2.  A minimum of 2 efforts that are considered acceptable and repeatable
following the overread are required to be eligible (seeSection 11.1.1 ).
3.Symptoms and rescue use: demonstrated and reported in a dail y diar y symptoms of 
asthma (a score of ≥1 on the day -time or night -time asthma s ymptom scores) and/or 
2016N298634_04 CONFIDENTIA L
HZA107116
36daily  albuterol/salbutamol on at least 3 of the last 7 consecutive da ys of the run -in 
period (not including the date of randomisation) .
4.Compliance with run -in medication: compliance is defined as use of run- in 
medication on at least 4 of the last 7 consecutive day s of the run- in period (not 
including the date of randomisati on)recorded in the electronic patient d iary.
5.Compliance with completion of the daily diary reporting: defined as completion 
of all questions on 4 out of the last 7 days during the run- in period (not including the 
date of randomisation).
8.4.2. Exclusion Criteria for Randomis ation to Treatment
1.Changes in asthma medication that occur after s creening.
2.Occurrence of a culture -documented or suspected bacterial or viral infection of the 
upper or lower respiratory  tract, sinus or middle ear during the run -in period that led 
to a change in asthma management or, in the opinion of the investigator, is expected 
to affect the participant ’s asthma status or the participant ’s ability  to participate in the 
study .
3.Evidence of an exacerbation, defined as a: 
deterioration of asthma requiring the use of oral corticosteroids for at least 3 days, 
or 
a depot corticosteroid injection, or 
an in- patient hospitalisation due to asthma that required sy stemic corticosteroids
between screening and r andomis ation.
4. Clinical visual evidence of orophary ngeal candidiasis at the Randomisation Visit.
5.Unable to use the ELLIPTA inhaler correctly .
9. TREATMENTS
Study  treatment is defined as an y investigational treatment(s), marketed product(s), 
placebo, or medical device (s)intended to be administered to a study  participant according 
to the study  protocol.
Investigational product will be supplied bytheClinical Trial Supply  group. The 
frequency  at which the investigational product will be supplied to each individual site 
will be adapted to the availabilit y of investigational product, recruitment capacit y of that 
site, and to the expiry  date of the investigational product.
9.1. Treatments A dministered
Details of study  treatments that will be administered in this study  are detailed in Table 2.
2016N298634_04 CONFIDENTIA L
HZA107116
37Table 2 Study  Treatments
Study Treatment 
Name:Fluticasone 
Furoate / 
Vilanterol 50/25 
mcg dry 
powder inhaler*Fluticasone 
Furoate / 
Vilanterol 
100/25 mcg dry 
powder i nhaler*Fluticasone 
Furoate 50 mcg 
dry powder 
inhaler **Fluticasone 
Furoate 100 
mcg dry powder 
inhaler **
Dosage 
formulation:Dry powder 
inhaler Dry powder 
inhalerDry powder 
inhaler Dry powder 
inhaler 
Unit dose 
strength(s)/Dosage 
level(s):FF 50 mcg & VI 
25 mcg per 
actuationFF 100 mcg & 
VI 25 mcg per 
actuationFF 50 mcg per 
actuationFF 100 mcg per 
actuation
Route of 
Administration: Inhaled Inhaled Inhaled Inhaled
Dosing 
instructions:Inhale once in 
the morningInhale once in 
the morningInhale once in 
the morningInhale once in 
the morning
Device: Ellipta Ellipta Ellipta Ellipta
Method of 
individualizing 
dosage:Inhalation (oral) Inhalation (oral) Inhalation (oral) Inhalation (oral)
*Dual Strip; **Single Strip
Fluticasone propionate mulitdose powder inhaler ( 100 mcg twice dail y) will be supplied 
by the Clinical Trial Supply  group for use during the run -in period. 
SABA inhalation aerosol (albuterol/salbutamol) will be provided locally  for sy mptomatic 
relief of asthma sy mptoms during the study .
9.1.1. Medical Devices
Peak flow meters will be provided b y GSK for use in this study ; however these devices
are not manufactured by , or on behalf of GSK.
Any malfunctions with the Ellipta inhaler should be reported and defective inhalers 
should be returned (see SRM for further details).
9.2. Dose Modification
Not applicable.
2016N298634_04 CONFIDENTIA L
HZA107116
389.3. Method of Treatment A ssignment
Participants are required to meet the inclusion criteria for randomisation to treatment 
detailed in Section 8.4. Participants meeting exclusion criteria for randomisation to 
treatment will not be randomised to treatment.
Participants will be randomised to 1 of 2 treatment arms using Interactive Voice/Web 
Response Sy stem ( IVRS/IWRS).
Before the stud y is initiated, the telephone number and call -in directions for the IVRS 
and/or the log in information and directions for the I WRS will be provided to each site.  
Study  treatment will be dispensed (according to treatment assigned using IVRS) at the 
study  visits summarised in SOA.  Returned study  treatment should not be re -dispensed to 
the participants.
9.4. Blinding
This isa double -blind study  and the following will apply :
The IVRS/I WRS will be programmed w ith blind -breaking instructions.  The blind 
may be broken if, in the opinion of the investigator, it is in the participant’s best 
interest for the investigator to know the study  treatment assignment.  GSK must be 
notified before the blind is broken unless identification of the study  treatment is 
required for a medical emergency  in which the knowledge of the specific blinded 
study  treatment will affect the immediate management of the participant’s condition 
(eg, antidote is available).  I n this case, GSK mus t be notified within 24 hours after 
breaking the blind. The date and reason that the blind was broken must be recorded 
in the source documentation and case report form ( CRF ), as applicable.
The date and reason for the unblinding must be fully  documented i n the CRF and 
source documentation. 
A subject may  continue in the study  if that subject’s treatment assignment is 
unblinded by  GSK Global Clinical Safety  and Pharmacovigilance (GCSP) personnel. 
The primary  reason for discontinuation (the event or conditi on which led to the 
unblinding) will be recorded in the CRF.
GSK’s GCSP staff may  unblind the treatment assignment for an y participant with an 
SAE. If the SAE requires that an expedited regulatory  report be sent to 1 or more 
regulatory agencies, a copy  ofthe report, identify ing the subject’s treatment 
assignment, may  be sent to investigators in accordance with local regulations and/or 
GSK policy .
9.5. Preparation/Handling/Storage/A ccountability
The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  treatment received and any  discrepancies 
are reported and resolved before use of the stud y treatment.
2016N298634_04 CONFIDENTIA L
HZA107116
39Only  participants enrolled in the study  may  receive study  treatment and only  
authorized site staff may  supply  or administer study  treatment. All study  treatments 
must be stored in a secure, environmentall y controlled, and monitored (manual or 
automated) area in accordance with the labeled storage conditions with access 
limited to the investigator and authorized site staff.
The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stud y treatment accountability, reconciliation, and record 
maintenance (i .e. receipt, reconciliation, and final disposition records).
Further guidance and information for the final disposition of unused study  treatment 
are provided in the study  reference manual (SRM ).
Under normal conditions of handling and administration, study  treatment is not 
expected to pose significant safety risks to site staff .  Take adequate precautions to 
avoid direct ey e or skin contact and the generation of aerosols or mists.  In the case 
of unintentional occupational exposure, notify  the monitor, Medic al Monitor and/or 
GSK study  contact.
A Material Safety  Data Sheet (MSDS)/equivalent document describing occupational 
hazards and recommended handling precautions either will be provided to the 
investigator, where this is required b y local laws, or is avail able upon request from 
GSK.
9.6. Treatment Compliance
Subject compliance with double -blind study  medication will be assessed from Visit 3
(Random isation visit) through to Visit 9 ( End of Treatment Period) b y reviewing the 
following:
1. ELLIPTA dose counter asse ssment at each visit.
Subjects whose compliance falls below 80% during the study  should be re -trained on 
appropriate dosing of study  drug, and may  be required to attend the clinic for an 
unscheduled visit.  
9.7. Concomitant Therapy
Any medication that is not p rohibited in I nclusion/Exclusion criteria section (see Section
8.1andSection 8.2)is allowed during the stud y, as long as the dose remains constant 
wherever possible and their use is not expected to affect the outcome of the study  
assessments.
Any medication or vaccine (including over -the-counter or prescription medicines, 
vitamins, and/or herbal supplements) that the participant is receiving at the t ime of 
enrolment or receives during the stud y must be recorded along with:
reason for use
2016N298634_04 CONFIDENTIA L
HZA107116
40dates of administration including start and end dates
dosage information including dose and frequency
The Medical Monitor should be contacted if there are an y questio ns regarding 
concomitant or prior therapy .
The study  site will supply  salbutamol /albuterol aerosol inhaler at Visit 1 for use as 
needed for the duration of the study.  Salbutamol /albuterol MDI will be administered 
with or without a spacer, to be used as de termined by  the investigator.  The use or non -
use of the spacer should be consistent for an individual participant throughout the study .
SABA (inhalation aerosol or nebuliser) use should be withheld for 4 hours prior to the 
FEV 1measurement at screening and at all future visits where FEV 1is measured.  
9.7.1. Prohibited Medications and Non- Drug Therapies
Note :  Participants should be treated as appropriate for asthma exacerbations without 
requirement to withdraw the participant from the study . 
Steroids will be an exclusion from randomisation if administered during the run -in period 
(apart from FP). However, they  should never be withheld if deemed necessary . 
Use of the following medications is prohibited according to the timeframes indicated
unless they  are deemed necessary  to treat an asthma exacerbation or another condition 
appropriatel y:
From screening visit (Visit 1) to Visit 9: L TRAs, ketotifen, nedocromil sodium, 
orally  inhaled sodium cromogl ycate, SABA/short -acting muscarinic antagonist 
(SAMA) combinations (e.g. Combivent ), and inhaled corticosteroids (except for FP 
which is given during the run- in).  
Within 4 weeks of Visit 1 : participants who have changed their asthma medication.
Within 4 weeks of Visit 1, or any time between Visit 1 to 9: theophy llines, oral 
long-acting beta 2 -agonists (e.g. bambuterol), inhaled long -acting beta 2 -agonists 
(e.g. salmeterol, formoterol), combination products containing inhaled long -acting 
beta 2- agonists (e.g. Seretide, Sy mbicort, Dulera) and inhaled l ong-acting 
anticholinergics (e.g. tiotropium).  Potent cy tochrome P450 3A4 (CYP3A4) inhibitors 
(e.g. clarithromy cin).  Prescription or over -the-counter medication that would 
significantl y affect the course of asthma or change in asthma medication, or inter act 
with study  drug including (but not limited to): anticonvulsants (barbiturates, 
hydantoins, carbamazepine); poly cyclic anti -depressants; oral, s ystemic or 
transdermal beta -adrenergic blocking agents; phenothiazines and monoamine oxidase 
inhibitors.
With in 6 weeks of Visit 1 or any time between Visit 1 to 9 : Oral corticosteroids.
NOTE:  During the double -blind treatment period subjects who require limited 
courses of oral corticosteroids should remain on study  treatment.
2016N298634_04 CONFIDENTIA L
HZA107116
41Within 12 weeks of Visit 1 or any t ime between Visit 1 to 9: sy stemic or depot 
corticosteroids, anti -immunoglobulin E (IgE) (e.g. Xolair), anti-interleukin (IL)5 (e.g. 
Nucala) immunosuppressive medications (immunotherap y for the treatment of 
allergies is allowed during the stud y provided it was initiated at least 4 weeks prior to 
Visit 1 and the participant remains in the maintenance phase throughout the study ).
Other:   a participant must not have used any  inhaled SABA within 4 hours of Visit 1.
9.8. Treatment after the End of the Study
Subjects will not receive any additional treatment from GSK after completion of the 
study  because other treatment options are available.
The investigator is responsible for ensuring that consideration has been given to the post -
study  care of the subject’s medical condition, whether or not GSK is providing specific 
post-study  treatment.
10. DISCONTINUA TION CRIT ERIA
10.1. Discontinuation of Study  Treatment
Participants that permanently stop study treatment are encouraged to remain in the 
study .  Participants have the right to d iscontinue study  treatment before the end of the 
study .  Participants who discontinue from study  treatment prematurel y (for any reason) 
should continue to be followed -up as per protocol until the completion of the follow -up 
assessments. The investigator mu st make every  effort to keep the participant in the study  
to collect efficacy  and safety  data.
Participant smay be discontinued from study treatment at any  time by  the i nvestigator if it 
is considered to be detrimental for them to continue on study treatment. Specificall y,a 
participant will be discontinued from study  treatment if he/she meets any  of the following 
criteria outlined below:
A participant becomes pregnant.
Female participants who reach menarche after Visit 1 and who do not agree to 
follow one of the options listed in the Modified L ist of Highl y Effective Methods 
for Avoiding Pregnancy  in FRP (which includes abstinence) as outlined in 
Section 14.4.
A participant meets the liver stopping criteria (see Section 10.1.1).
A participant meets the QTc stopping criteria (see Section 10.1.2 ).
A participant may  discontinue study  treatment at any  time at his/her own request.  An 
Early Treatment Discontinuation Visit should be co nducted within approximately  
24hours of the participant stopping study  medication. In the event a participant 
discontinues study  treatment at or during a scheduled visit, an Earl y Treatment 
Discontinuation Visit is not required; however, all study  procedures scheduled at an Early  
2016N298634_04 CONFIDENTIA L
HZA107116
42Treatment Discontinuation Visit must be performed at this visit instead and reasons for 
treatment discontinuation should be collected . These participants will not be allowed to 
restart stud y treatment ; however, participants will be asked to continue to follow the 
regular visit schedule, including the completion of the daily  electronic patient diary (until 
Visit 6), and attending the clinic at Visit 6 to obtain serial FEV 1measurements. The 
investigator should prescribe appropria te asthma medication to participants who 
discontinue study  treatment and elect to continue in the study . After treatment 
discontinuation, the prohibited medications listed in e xclusion criterion 7are no longer 
applicable. Every  effort will be made to co ntact participants who do n ot attend the End 
of Treatment V isit to collect information on any  AEs, SAEs and exacerbations, and to 
collect the e -diary .
10.1.1. Liver Chemistry Stopping Criteria
There are no scheduled blood tests in this study , apart from the collec tion of a fasting 
glucose blood sample.  If however the participant has a routine blood test during the 
study  and the results suggest abnormal liver function, then the liver stopping criteria will 
apply .
Liver chemistry stopping and increased monitoring criteria have been designed to 
assure participant safety  and evaluate liver event etiology (in alignment with the Food 
and Drug Administration [ FDA ]premarketing clinical liver safety  guidance). These 
protocol guidelines are in alignment with FDA premarketing clinical liver safet y 
guidance:
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf.
Discontinuation of study  treatment for abnormal liver tests should be considered by  the 
investigator when a par ticipant meets one of the conditions outlined in the algorithm or if 
the investigator believes that it is in the best interest of the participant. 
2016N298634_04 CONFIDENTIA L
HZA107116
43Algorithm A: Phase III -IV Liver Chemistry Stopping and Increased Monitoring 
Algorithm
Liver Safet y Require d Actions and Follow up Assessments Section can be found in 
Appendix 6.

2016N298634_04 CONFIDENTIA L
HZA107116
44Algorithm B: Phase III -IV Liver Chemistry Increased Monitoring Algorithm with 
Continued Therapy for ALT  3xULN but <8xULN
Liver Safet y Required Actions and Follow up Assessments Section can be found in 
Appendix 6.
10.1.2. QTc Stopping Criteria
ECGs will be performed as outlined in the SOA ( Table 1 ).  QTcF will be used for each 
individual participant to determine eligibility  for and discontinuation from the study .  
The QTc should be based on single or averaged QTc values of triplicate 
electrocardiograms obtained over a brief (e.g. 5 to 10 minute) rec ording period.  
A participant who meets thebulleted criteria based on the average of triplicate ECG 
readings will be withdrawn from study  treatment:
QTcF> 500 msec OR Uncorrected QT > 600 msec
Change from baseline of QTc F> 60 msec
For patients with und erlying bundle branch block, follow the discontinuation criteria 
listed below:

2016N298634_04 CONFIDENTIA L
HZA107116
45Baseline QTc Fwith Bundle Branch 
BlockDiscontinuation QTc Fwith Bundle 
Branch Block
<450 msec >500 msec
450–480 msec ≥530 msec
See the SoA for data to be collected at the time of treatment discontinuation and follow -
up and for an y further evaluations that need to be completed.
10.2. Withdrawal from the Study
A participant may  withdraw from the study  at an y time at his/her own request or 
at the request of his/her legal guardian(s) ,or may  be withdrawn at any  time at the 
discretion of the investigator for safet y, behavioural , or administrative reasons.
If the participant withdraws assent or if his/her legal guardian(s) withdraw 
consent for disclosure of future information, the sponso r may  retain and 
continue to use any data collected before such a withdrawal of consent.
If a participant withdraws from the study , he/she may  request destruction of any  
samples (e.g. saliva) taken and not tested, and the investigator must document 
this in the site study  records.
Refer to the SO A (Table 1) for data to be collected at the time of study  
discontinuation and follow- up and for an y further evaluations that need to be 
completed.
If the participant chooses to withdraw from the study , all study -related medications and 
other study  related materials should be returned to the site by  the participant.  An Earl y 
Withdrawal Visit should be conducted wi thin approximately  24 hours of the participant 
stopping study  medication.  I n the event a participant withdraws at or during a scheduled 
visit, an Early  Withdrawal Visit is not required; however, all study  procedures scheduled 
at an Earl y Withdrawal Visit must be performed at this visit instead.  A follow -up phone 
contact or video -call should be made 7 day s after the Earl y Withdrawal Visit.  The 
primary  reason for stud y treatment discontinuation or study  withdrawal will be recorded 
in the electronic case re port form (eCRF) and an y data collected up until the point of 
withdrawal will be used in the data analy ses.
10.3. Lost to Follow Up
A participant will be considered lost to follow -up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contacted b y the study  site. 
The following actions must be taken if a participant fails to return to the clinic for a 
required stud y vis it:
The site must attempt to contact the participant and reschedule the missed visit 
as soon as possible and counsel the participant on the importance of maintaining 
2016N298634_04 CONFIDENTIA L
HZA107116
46the assigned visit schedule and ascertain whether or not the participant wishes to 
and/or should continue in the study .
Before a participant is deemed lost to follow up, the investigator or designee 
must make every  effort to regain contact with the participant or legal guardian(s)
(where possible, 3telephone calls and, if necessary , a certified letter to the 
participant’s last known mailing address or local equivalent methods). These 
contact attempts should be documented in the participant’s medical record.
Should the participant continue to be unre achable, he/she will be considered to 
have withdrawn from the study  with a primary  reason of lost to follow -up. 
11. STUDY A SSESSMENTS A ND PROCEDURES
Study  procedures and their timing are summarised in the SO A (Table 1). 
Protocol waivers or exemptions are notallowed.
Immediate safety  concerns should be discussed with the sponsor immediately  upon 
occurrence or awareness to determine if the participant shou ld continue or 
discontinue study  treatment.
Adherence to the stud y design requirements, inc luding those specified in the SO A, is 
essential and required for study conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening 
log to record details of all participants screened and to confirm eligibility  or record 
reasons for screening failure, as applicable. 
Procedures conducted as part of the participant’s routine clinical management (eg, 
blood count) and obtained before signing of ICF may  be utilized for screening or 
baseline purposes provided the procedure met the protocol- specified criteria and was 
performed within the time frame defined in the SO A.
A 2mL blood sample will be collected for the assessment of fasting blood glucose
from each participant at Visits 1 and 9 (and ETD/DW , and if repeat test is required at 
Visit 1 ).
11.1. Efficacy  Assessments
The timing of all efficacy assessments is provided in the SOA.
11.1.1. FEV 1
Spirometry  at Visit 2, Visit 4, Visit 5 (if applicable), ETD and EW may be collected at 
home or in the clinic. At -home spirometry  must be done using a Masterscope provided by 
the spirometry  vendor, ERT (with central over -read). Home nurses will be experienced in 
spirometry  and will be trained by  ERT. 
Spirometry  at Visit 1 and Visit 6 must be done in the clinic. 
2016N298634_04 CONFIDENTIA L
HZA107116
47Spirometry  will be performed to assess FEV 1. It will be measured using a sta ndardised 
calibrated spirometer .  At least 3 spirometry  manoeuvres (from a maximum of 8 
attempts) should be achieved on each occasion that spirometry  assessments are 
performed. For all spirometry  data collected, best spirometry  effort will be selected from 
a measurement that meets the American Thoracic Society  (ATS)/ European Respiratory  
Society  (ERS) guidelines. 
For both the pre -bronchodilator and post -bronchodilator time points a t screening (Visit 
1), there must be a minimum of 2 spirometry  efforts that are considered acceptable (not
necessarily  repeatable) to be eligible for the study .  
At the pre -randomisation visit (Visit 2), there must be a minimum of 2 spirometry  efforts 
that are considered acceptable and repeatable (available and reviewed at Visit 3) in order 
to be eligible for randomisation.
For all data (including both pre -dose and serial FEV 1) collected during the treatment 
period ( Visit s 4 and 6, and where collected at Visit 5) and ETD/EW, there must be a 
minimu m of 2 efforts that are considered acceptable (not necessaril y repeatable).
Predicted FEV 1values will be based on Quanjer (GLI2012) [ Quanjer , 2012] .
For a ll visits and time points, spirometry  will be subject to a central overread. The final 
value after the overread is the value that will be databased and anal ysed. This is also the 
value that will be used to determine eligibility  for the spirometry  at Visits 1 and 2.
Participants must withhold from using salbutamol /albuterol (inhalation aerosol or 
nebuliser) for 4 hours prior to FEV 1measurements. In addition, p articipants must not
take their stud y drug (if applicable) prior to the visit and performing their pre -dose FEV 1
measurement. 
Pre-dose FEV 1will be measured in the morning between 6.00am and 11.00am.  
11.1.1.1. Serial FEV 1
Serial FEV 1measurements at Visit 6 will occur at 15 minutes pre -dose and 30, 60, 
120,180, and 240 minutes post dose.
If the participant is unable to attend the clinic at V isit 6 for any reason, every attempt 
should be made to bring the participant back to the clinic to collect serial spirometry  as 
soon as possible between Visit 6 (Week 12) and Visit 9 (Week 24) . 
Any serial measurements that are collected after week 12 will be used in the primary  
analysis, which is considered acceptable as the drug effect is expected to have reached a 
plateau b y 3 months post -randomisation, and should not significantl y change afterwards .
11.1.1.2. Reversibility
At Visit 1, to check eligibility , reversibility  in FEV 1will be assessed.  
2016N298634_04 CONFIDENTIA L
HZA107116
48FEV 1will be measured within 15 to 40 minutes following 2 to 4 inhalations of 
albuterol/salbutamol (a spacer device may  be used if required) or onenebulis ed treatment 
with albuterol/salbutamol solution. Subjects who fail to demonstrate a 12% increase in 
FEV 1will not be eligible to take part in the study (see Section 8.1. for further 
information).
Percent reversibility  will be calculated as follows:
(Post -bronchodilator FEV 1–Pre-bronchodilator FEV 1) X 100
Pre-bronchodilator FEV 1
11.1.2. Electronic Daily  Diaries
Participants will be issued with an electronic patient diary  and instructed on how to 
complete it.  The following parameters will be recorded in the electronic patient diary
from Visits 1 to 6 only: 
Daily  PEF (morning and evening) (see Section 11.1.2.1 for further details)
Daily  asthma sy mptom scores (morning and evening) (see Section 11.1.2.2 for 
further details)
Number of inhalations of rescue albuterol/sal butamol inhalation aerosol used during 
the day  and night.  Note:   Rescue medication taken as preventative treatment before 
exercise will be excluded from this count and should not be entered into the daily  
eDiary .
11.1.2.1. Daily  PEF
PEF will be measured in the morning and evening using a peak flow meter that will be 
issued to participants at Visit 1 . The best of three attempts will be recorded in the 
electronic patient diary . 
PEF will be measured prior to any  study  medication and any  rescue albuterol/salbutamol 
inhalation aerosol use.
11.1.2.2. Asthma Sy mptom Scores
The following should be recorded in the electronic patient diary  in the evening at bedtime 
(PM) before taking an y rescue or stud y medication and before PEF measurement s:
Day-time Sy mptom Score:
o
o
o
o
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or 
indices, which are protected by third party copyright laws and therefore have been excluded.
2016N298634_04 CONFIDENTIA L
HZA107116
49o
o
The following will be recorded every  day in the eDiary  in the morning (AM) upon rising 
before taking an y rescue medication and before PEF measurement:
Night -time Sy mptom Score:
o
o
o
o
o
11.1.3. Questionnaires
Questionnaires should be completed before an y procedures are performed on the 
participant to avoid influencing the participant’s response. To avoid biasing responses, 
the participants should not be told the results of diagnostic tests prior to completing the 
questionnaires and it is recomm ended that the questionnaires be administered at the same 
time of day  during each visit (as applicable).  Adequate time must be allowed to complete 
all items on the questionnaires; the questionnaires must be reviewed for completeness 
and, if necessary, the participant must be encouraged to complete any  missing 
assessments or items.
11.1.3.1. Childhood A sthma Control Test and Asthma Control Test
The Childhood Asthma Control Test (cACT) or Asthma Control Test (ACT) will be 
completed at Visit 1 and Visit 3 only as part of the eligibility  and randomisation criteria.  
The cACT will be completed b y participants aged 5 to 11 years old and the ACT will be 
completed b y participants 12 to 1 7years old.  
The c ACT is a 7
-item questionnaire to measure asthma control in children.  I t is designed 
for completion by the participant and by the participant’s parent/legal guardian.  The 
child should complete questions 1- 4 as independently  as possible; however, if a child has 
difficulty  with completion, the parent/legal guard ian can provide assistance.  The 
parent/legal guardian should complete questions 5- 7 without letting their child’s 
responses influence their answers.  The investigator or designated stud y site personnel 
should encourage the child not to skip questions on t he cACT or take breaks during the 
completion of the paper questionnaire.
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, 
which are protected by third party copyright laws and therefore have been excluded.
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or 
indices, which are protected by third party copyright laws and therefore have been excluded.
2016N298634_04 CONFIDENTIA L
HZA107116
50The ACT is a five -item questionnaire, which has been developed as a measure of 
subjects’ asthma control that can be quickl y and easily  completed in clinical practice. The 
questions ar e designed to be self- completed by  the subject. To avoid biasing responses, 
the subjects should not be told the results of diagnostic tests prior to completing the 
questionnaire and should be completed before an y procedures are performed on the 
subject to avoid influencing the subject’s response. Adequate time should be allowed to 
complete all items on the ACT.
11.1.3.2. Asthma Control Questionnaire A CQ-5
The ACQ -5 is a five -item questionnaire, which has been developed as a measure of 
participants’ asthma control tha t can be quickl y and easily  completed [ Juniper , 2005a ].  
The questions are designed to be self -completed by  the participant.  
Participants will complete the ACQ -5 at Vi sits 3, 6 and 9
.  The ACQ 5 includes five 
questions (concerning nocturnal awakening, waking in the morning, activity limitation, 
shortness of breath and wheeze) which enquire about the frequency  and/or severit y of 
symptoms over the previous week.  The response options for all these questions consist 
of a zero  to six ) scale. A score of 
<0.75 indicates well -controlled asthma and a score 1.5 indicates poorly  controlled 
asthma [ Juniper , 2006]. A change of 0.5 in score suggests a clinicall y important change 
in score [ Juniper , 2005b].
11.1.4. Asthma exacerbation
An exacerbation is defined as deterioration of asthma requiring the use of sy stemic 
corticosteroids (tablets, suspension, or injection) for at least 3 day s or a single depot 
corticosteroid 
injection or an in -patient hospitalisation or emergency  department visit due 
to asthma that required systemic corticosteroids.  Investigators should follow current 
asthma management guidelines in the evaluation of patients with worsening of asthma 
and in t he management of acute exacerbations.  Asthma exacerbations should not be 
recorded as an AE, unless they  meet the definition of an SAE.  For the purposes of this 
study , asthma exacerbations will be collected and recorded on the exacerbations log in 
the eCR F.  The treatment details must also be recorded in the eCRF.
11.2. Adverse Events
The definitions of an AE or SAE can be found in Appendix 3.
The investigator and any designees are responsible for detecting, documenting, and 
reporting events that meet the definition of an AE or SAE and remain responsible for 
following up AE sthat are serious, considered related to the study  treatment or the study , 
or that caused the participant to discontinue the study  treatment study  (see Section 10). 
11.2.1. Time Period and Frequency  for Collecting A E and SA E 
Information
All SAE s
will be collected from signing of the ICFuntil the follow -up call at the
time points specified in the SO A (Section 2).
CCI
CCI
2016N298634_04 CONFIDENTIA L
HZA107116
51All AEs will be collected from the start of treatment until the follow-up call at 
the time points specified in the S OA (Section 2).
Medical occurrences that begin before the start of study  treatment but after 
obtaining informed consent will be recorded on the Medical History /Current 
Medical Conditions section of the CRF not the AE section.
All SAE swill be recorded and reported to the sponsor or designee within 
24hours, as indicated in Appendix 3. The investigator will submit any  updated 
SAE data to the sponsor within 24 hours of it being available.
Investigators are not obligated to activel y seek AEs or SAEs in former study  
participants. However, if the investigator learns of any  SAE, including a death, 
at an y time after a participant has been discharged from the study, and he/she 
considers the event to be reasonabl y related to the study  treatment or study  
participation, the investigator must promptly  notify  the sponsor.
The method of recording, evaluating, and assessing causality  of AEs and SAEs
and the procedures for completing and transmitting SAE reports are provided in 
Appendix 3.
11.2.2. Method of Detecting A Es and SA Es
Care will be taken not to introduce bias when detecting AE and/or SAE. Open -ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrence. 
11.2.3. Follow -up of A Es and SA Es
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subs equent visits/contacts. All SAEs, [and non serious AEs of special 
interest (as defined in Section 3.3)], will be followed until the event is resolv ed, 
stabilized, otherwise explained, or the participant is lost to follow- up (as defined in 
Section 10.3). Further information on follow -up procedures is given in Appendix 3.
11.2.4. Regulatory  Reporting Requirements for SA Es
Prompt notification by  the investigator to the sponsor of a SAE is essential so 
that legal obligations and ethical responsibilities towards the safet y of 
participants and the safety  of a study  treatment under clinical investigation ar e 
met. 
The sponsor has a legal responsibility  to notify  both the local regulatory  
authority  and other regulatory  agencies about the safet y of a stud y treatment 
under clinical investigation. The sponsor will comply  with country -specific 
regulatory  require ments relating to safet y reporting to the regulatory authority, 
IRBs/IECs, and investigators.
Investigator safety reports must be prepared for suspected unexpected serious 
adverse reactions (SUSAR) according to local regulatory  requirements and 
sponsor pol icy and forwarded to investigators as necessary .
2016N298634_04 CONFIDENTIA L
HZA107116
52An investigator who receives an investigator safety report describing a nSAE or 
other specific safet y information (e.g. summary  or listing of SAE) from the 
sponsor will review and then file it along with the Investigator’s Brochure and 
will notify  the IRB/IEC, if appropriate according to local requirements.
11.2.5. Death Events
For all deaths, whether or not they  are considered SAEs, specific Death sections of the 
CRF will be required to be completed. These sections include questions regarding 
cardiovascular (including sudden cardiac death) and non- cardiovascular death. 
The Death CRF is provided immediately after the occurrence or outcome of death is 
reported. Initial and follow-up reports regarding death must be c ompleted within 1week 
of when the death is reported.
11.2.6. Pregnancy
Details of all pregnancies in female participants will be collected after the start of 
study  treatment and until the last follow- up visit .
If a pregnancy  is reported, the investigator should inform the CRO within 24 hours 
of learning of the pregnancy  and should follow the procedures outlined in 
Appendix 4.
Abnormal pregnancy  outcomes (e .g.spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy ) are considered SAE.
11.2.7. Treatment of Overdose
For this study , any  dose of FF/VI combination or FF that is more than that per mitted by  
the protocol within a 24 -hour time period that results in clinical signs or symptoms will 
be considered an overdose.
GSK does not recommend specific treatment for an overdose.
In the event of an overdose, the investigator should:
1.Contact the Medical Monitor immediately .
2.Closely  monitor the participant for AE/SAE and laboratory  abnormalities including a 
morning cortisol (to be assessed based on the duration and magnitude of the 
overdose) until FF and / or VI (depending on treatment group) can n o longer be 
detected s ystemically  (at least 5 day s from last dose administered ).
3.Obtain a plasma sample for PK anal ysis within 1 to 5 days from the date of the last 
dose of study  treatment if requested by  the Medical Monitor (determined on a case-
by-case b asis).
4.Document the quantit y of the excess dose as well as the duration of the overdosing in 
the CRF.
2016N298634_04 CONFIDENTIA L
HZA107116
53Decisions regarding dose interruptions or modifications will be made by  the investigator 
in consultation with the Medical Monitor based on the clinical ev aluation of the 
participant.
11.2.8. Medical Device Deficiencies
Medical devices are being provided for use in this study . To fulfil regulatory  reporting 
obligations worldwide, the investigator is responsible for the detection and 
documentation of events meeting the definitions of device deficiency  that occur during 
the study  with such devices.
The definition of a Medical Device Deficiency  can be found in Section 14.7 Appendix 7 .
NOTE: Deficiencies fulfilling the definition of an AE/SAE will also follow the processes 
outline d in Appendix 7 of the protocol. 
11.2.8.1. Time Period for Detecting Medical Device Deficiencies
Medical device deficiencies that result in an incident will be detected , 
documented, and reported during all periods of the study  in which the medical 
device is used. 
If the investigator learns of an y device deficiency at an y time after a participant 
has been discharged from the study , and such device deficiency  is considered 
reasonabl y related to a medical device provided for the study , the investigator will 
promptly  notify  the sponsor.
The method of documenting Medical Device Incidents is provided in Appendix 7 .
11.2.8.2. Follo w-up of Medical Device Deficiencies
Follow -up applies to all participants, including those who discontinue study  
intervention or the study .
The investigator is responsible for ensuring that follow-up includes an y supplemental 
investigations as indicated to elucidate the nature and/or causality  of the deficiency .
New or updated information will be recorded on the originally completed form with 
all changes signed and dated by  the investigator.
11.2.8.3. Prompt Reporting of Medical Device Deficiencies to Sponsor
Device deficiencies will be reported to the sponsor within 24 hours after the 
investigator determines that the event meets the protocol definition of a device 
deficiency .
The Medical Device Deficie ncy Report Form will be sent to the CRO by the 
electronic data collection tool . If the electronic data collection tool is unavailable, 
then the paper SAE data collection tool should be utilized.
2016N298634_04 CONFIDENTIA L
HZA107116
54The CRO will be the contact for the receipt of device defici ency  reports.
11.2.8.4. Regulatory  Reporting Requirements for Medical Device Incidents
The investigator will promptly  report all deficiencies occurring with any  medical 
device provided for use in the study  in order for the sponsor to fulfill the legal 
responsibility  to notify  appropriate regulatory  authorities and other entities about 
certain safet y information relating to medical devices being used in clinical studies.
The investigator, or responsible person according to local requirements (e.g., the h ead 
of the medical institution), will comply  with the applicable local regulatory 
requirements relating to the reporting of device deficiencies to the IRB/IEC.
11.3. Safet y Assessments
Planned time points for all safety  assessments are provided in the SO A.
11.3.1. Physical Examination
A complete ph ysical examination will include, at a minimum, assessments of the 
Skin, Cardiovascular, Respiratory , Gastrointestinal and Neurological s ystems. 
Height and weight will also be recorded.
Investigators should pay  special attention to clinical signs related to previous 
serious illnesses.
11.3.2. Orophary ngeal Examination
Orophary ngeal examination for visual evidence of oral candidiasis will be carrie d out at 
as outlined in the SOA . If the visual orophary ngeal examination is abnormal prior t o 
randomisation the participant must not be randomised.  
If there is any visual clinical evidence of oral candidiasis during the double -blind 
treatment period of the study , subjects may  continue in the study  and appropriate anti-
infective therap y should b e instituted at the discretion of the investigator. If the subject 
requires therap y with a medication prohibited b y the protocol, the subject should be 
treated appropriatel y and discontinued from study  treatment. All visual clinical evidence 
of candidiasis must be reported as an AE.
The results of the orophary ngeal examinations and any  relevant pharmacotherapy  will be 
recorded in the subject’s clinic notes and eCRF.
11.3.3. Vital Signs
Vital signs (s ystolic and diastolic blood pressure and heart rate) will be measured at 
Screening onl y. The measurement will be taken after 5 minutes rest prior to spirometry .  
One reading of blood pressure and pulse will be taken and will only  be repeated if out of 
the normal range.    
2016N298634_04 CONFIDENTIA L
HZA107116
5511.3.4. Electrocardiograms
12-Lead electroc ardiogram measurements will be performed at Visit 1, Visit 9, and the 
Early Treatment Discontinuation/ Early  Withdrawal Visit.   
The 12- lead ECG will be recorded at 25 mm/sec and will consist of a recording of leads I, 
II, III, aVR, aVL, aVF and V1 to V6 and 10 seconds recording of lead II (rhy thm strip).  
At least 3 complete evaluable complexes per lead will be recorded. The follow ing ECG 
parameters will be determined.  Single 12- lead ECG will be obtained as outlined in the 
SOA using an ECG machine that automatically  calculates the heart rate and measures PR, 
QRS, QT, and QTc intervals. Refer to Section 10.1.2 for QTc withdrawal criteria and 
additional QTc readings that may  be necessary .  
Further details on ECG measurements will be provided in the SRM.
11.3.5. Clinical Safety  Laborat ory Assessments
No clinical laboratory  tests will be performed in this study , except for the collection of a 
2ml fasting glucose blood sample at the Screening Visit (Visit 1) and Visit 9 (End of 
Treatment ) or at the ETD/EW visit if applicable. A central laboratory  will be used.
If laboratory  values from non- protocol specified laboratory  assessments performed at the 
institution’s local laboratory  require a change in participant management or are 
considered clinically  significant by  the investiga tor (eg, SAE or AE or dose 
modification), then the results must be recorded in the CRF.
11.4. Pharmacokinetics
Pharmacokinetic parameters are not evaluated in this study .
11.5. Pharmacody namics
Pharmacod ynamic parameters are not evaluated in this study .
11.6. Genetics
A 2 mL saliva sample for deox yribonucleic acid (DNA) isolation will be collected from 
participants who have consented to participate in the genetics anal ysis component of the 
study . Participation is optional. Participants who do not wish to participate in the genetic 
research may  still participate in the study .
In the event of DNA extraction failure, a replacement genetic sample may  be requested 
from the participant. Signed informed consent will be required to obtain a replacement 
sample unless it was include d in the original consent.
See Appendix 5for information regarding genetic research. Details on processes for 
collection and shipment and destruction of t hese samples can be found in the SRM.
2016N298634_04 CONFIDENTIA L
HZA107116
5611.7. Biomarkers
Biomarkers are not evaluated in this study .
11.8. Health Economics OR Medical Resource Utilization and 
Health Economics
Health Economics/Medical Resource Utilization and Health Economics parameters are 
not evaluated in this study.
12. STATISTICA L CONSIDER ATIONS
12.1. Sample Size Determination
12.1.1. Sample Size A ssumptions
Approximately  870 participants will be randomised in this study  in a ratio of 1:1 giving 
435 randomised participants per arm in the 5 -17 years old population. There will be 652 
randomised participants who will be 11 y ears old or less at screening, giving 326 
randomised participants per arm in the 5 -11 years old population.
12.1.1.1. Sample Size A ssumptions for 5 -17 Years Old Population
The sample size calculation for the 5 -17 years old population is based on the primary  
efficacy  endpoint of weighted mean FEV 1(0-4 hours). The sample size allows for up to 
20% of participants to not contribute to the primary  endpoint gi ving a total of 348 
evaluable participants per arm.
The standard deviation is assumed to be 280mL  for 5 -11 year olds and 500mL  for 12-17 
year olds based on previous studies. Using the assumed representation across the age 
ranges (652 and 218 randomized par ticipants, respectivel y), a standard deviation of 
348mL  has been assumed for the 5 -17 years old population based on a weighted average 
of the variances (i.e. assuming equal means).
The sample size has 93% power, based on a true population difference of 90m L and 
significance declared at the two-sided 5% significance level. The smallest observed effect 
predicted to result in a statistically  significant difference between treatment groups is 
52mL .
12.1.1.2. Sample Size A ssumptions for 5 -11 Years Old Population
The sampl e size calculation for the 5 -11 years old population is based on the primary  
efficacy  endpoint of AM PEF and on the nominated powered secondary  endpoint of 
change from baseline in rescue -free 24-hour periods. The sample size allows for up to 4% 
of particip ants to not contribute to either endpoint giving a total of 312 evaluable 
participants per arm.
For the primary  endpoint of AM PEF, a standard deviation of 30 L/min is assumed, based 
on previous studies. The sample size has 91% power, based on a true popul ation 
2016N298634_04 CONFIDENTIA L
HZA107116
57difference of 8 L/min and significance declared at the two -sided 5% significance level. 
The smallest observed effect predicted to result in a statistically  significant difference 
between treatment groups is 4.7 L /min.  
For the nominated powered seco ndary  endpoint of change from baseline in rescue- free 
24-hour periods, a standard deviation of 30% is assumed, based on previous studies. The 
sample size has 99% power, based on a true population difference of 10% and 
significance declared at the two- sided 5% significance level. The smallest observed effect 
predicted to result in a statistically  significant difference between treatment groups is 
4.7%.  
Assuming a correlation of 0.1 between the primary endpoint and the nominated powered 
secondary  endpoint, the overall power for both endpoints in the 5 -11 years old population 
is 90%.
12.1.2. Sample Size Sensitivity
The standard deviation assumptions are based on estimates from previous studies. Table 
3presents the power achieved for the FF/VI versus FF treatment comparison in the 5 -17 
yea rs old population with the proposed sample size, should the assumption around the 
standard deviation of the data change. Table 4 presents the power achieved for the FF/VI 
versus FF treatment comparison in the 5- 11 years old population with the proposed 
sample, should the assumptions around the standard deviation of the data change. In each 
case, the actual assumptions used in the sample size calculations are shaded in grey.
Table 3 Impact of Standard Deviation on Power for 5 -17 Years Old 
Population
Standard Deviation Power (%)
Weighted Mean FEV 1(0-4 hours):300mL 98
325mL 95
348mL 93
375mL 89
400mL 84
Table 4 Impact of Standard Deviation on Power for 5 -11 Years Old 
Population
Standard 
DeviationPower (%) for 
Individual 
EndpointsOverall Power (%) 
Across Both 
Endpoints
AM PEF:
% Rescue -free 24 hr periods:20 L/min
20%>99
>99>99
AM PEF:
% Rescue -free 24 hr periods:25 L/min
25%98
>9998
AM PEF:
% Rescue -free 24 hr periods:30 L/min
30%91
9990
AM PEF:
% Rescue -free 24 hr periods:35 L/min
35%82
9577
2016N298634_04 CONFIDENTIA L
HZA107116
58Standard 
DeviationPower (%) for 
Individual 
EndpointsOverall Power (%) 
Across Both 
Endpoints
AM PEF:
% Rescue -free 24 hr periods:40 L/min
40%70
8862
12.1.3. Sample Size Re -estimation
No sample size re -estimation is planned.
12.2. Populations for A nalyses
For purposes of analy sis, the following populations are defined:
Population Description
Total Population The Total Population will comprise all participants screened and for 
whom a record exists on the study database and will be used for the 
tabulation and listings of reasons for withdrawal before 
randomisation .
ITT (5 -17 Years Old) 
PopulationThe ITT (5 -17 Years Old) Population will comprise all participants 
randomised to treatment and who received at least 1 dose of study 
medication. Randomised participants will be assumed to have 
received study medication unless definitive evidence to the contrary 
exists. Outcomes will be reported according to the randomised
treatment allocation. This will constitute one of the two primary 
populations for all efficacy measures and safety measures.
ITT (5 -11 Years Old) 
PopulationThe ITT (5 -11 Years Old) Population will be a subset of the ITT (5-
17 Years Old) Population for subjects aged 11 years old or younger 
at screening. Outcomes will be reported according to the 
randomised treatment allocation. This will constitute one of the two 
primary populations for all efficacy measures and safety measures.
12.3. Statistical A nalyses
12.3.1. Hypotheses
The primary  efficacy  endpoint for the 5- 17 years old population is weighted mean FEV 1
(0-4 hours). For the 5 -11 years old population the primary  effica cy endpoint is the change 
from baseline in AM PEF and the nominated powered secondary  endpoint is the change 
from baseline in rescue -free 24-hour periods. For each of these endpoints there will be a 
single inequalit y comparison of FF/VI versus FF. Demonstr ation of efficacy  for each of 
these inequality comparisons will be based on a hypothesis testing approach, whereby  the 
null hy pothesis is that there is no difference between treatment groups for the endpoint of 
2016N298634_04 CONFIDENTIA L
HZA107116
59interest and the alternative hy pothesis is th at there is a difference between treatment 
groups.  
A 2-sided 5% risk associated with incorrectl y rejecting an y of the null hypotheses 
(significance level) is considered acceptable for this study . As the comparisons on the 5-
17 years old population and th e 5-11 years old population are being made for differ ent 
purposes they  will each have distinct multiple testing strategies which will be assessed 
separately .  
For each of the two populations, in order to account for multiplicity  across the key  
endpoints, a step- down closed testing procedure will be applied to the inequality  
comparison of FF/VI versus FP whereby this comparison will be required to be 
significant at the 0.05 level for the primary  endpoint in order to infer on the secondary  
endpoints and infe rence for a test in the pre -defined hierarch y of secondary endpoints is 
dependent upon statistical significance having been achieved for the previous comparison 
in the hierarch y of secondary  endpoints. If a given statistical test fails to reject the null 
hypothesis of no treatment difference at the significance level of 0.05, then all tests lower 
down in the hierarch y will be interpreted as descriptive only.
Figure 2 Statistical Testing Strategy  for 5 -17 Years Old Population
Testing of each endpoint is dependent on significance at the 0.05 level having been achieved 
on the previous endpoint in the hierarchy.
Primary Efficacy Endpoint
1) Weighted mean FEV 1(0-4 hours): FF/VI vs. FF
Secondary Efficacy Endpoints
2) Rescue- free 24 hour periods: FF/VI vs. FF
3) Symptom -free 24 hour periods: FF/VI vs. FF
4) AM FEV 1: FF/VI vs. FF
5) AM PEF : FF/VI vs. FF
6)ACQ : FF/VI vs. FF
2016N298634_04 CONFIDENTIA L
HZA107116
60Figur e 3 Statistical Testing Strategy  for 5 -11 Years Old Population
The treatment comparisons defined as part of the multiple testing strategy  will be limited 
to the specified key  comparisons shown in Figure 2 and Figur e 3. Anal yses of other 
efficacy measures in either population for the FF/VI versus FF treatment comparison are 
nested under the secondary  efficacy  measures and no multiplicity  adjustment is planned 
for these other efficacy  endpoints.
In each population, if significance is achieved f or the FF/VI versus FF treatment 
comparison on the primary  efficacy  endpoint, then the secondary  endpoints will be tested 
in a closed -testing manner using the hierarchy  of comparisons. If significance is also 
achieved for each of the secondary  efficacy  endpoints, then all other efficacy  endpoints 
will be tested for the FF/VI versus FF treatment comparison without further multiplicity  
adjustment.
12.3.2. Treatment Comparisons
12.3.2.1. Primary  Comparison of Interest
The primary  treatment comparison for the 5- 17 years old population will be FF/VI versus 
FF for the primary  efficacy  endpoint of weighted mean FEV 1(0-4 hours) at week 12.
The primary  treatment comparison for the 5- 11 years old population will be FF/VI versus 
FF for the primary  efficacy  endpoint of change from baseline in AM PEF averaged over 
weeks 1 -12.
12.3.2.2. Other Comparisons of Interest
The primary  treatment comparison of FF/VI versus FF will also be performed for the 
secondary  and other efficacy  endpoints.Testing of each endpoint is dependent on significance at the 0.05 level having been achieved 
on the previous endpoint in the hierarchy.
Primary Efficacy Endpoint
1)AM PEF : FF/VI vs. FF
Secondary Efficacy Endpoints
2) Rescue -free 24 hour periods: FF/VI vs. FF
3) Symptom -free 24 hour periods: FF/VI vs. FF
4) AM FEV 1: FF/VI vs. FF
5) ACQ : FF/VI vs. FF
6) Weighted mean FEV 1(0-4 hours): FF/VI vs. FF
2016N298634_04 CONFIDENTIA L
HZA107116
6112.3.3. Key Elements of A nalysis Plan
The FF/VI 50/25 mcg and FF/VI 100/25 mcg treatment groups will be combined into one 
FF/V I treatment group for the purpose of reporting. Similarly , the FF 50 mcg and FF 100 
mcg treatment groups will be combined into one FF treatment group for the purpose of 
reporting.
In this stud y, every effort will be made for participants who withdraw from study  
medication to remain in the study  and continue with the normal visit schedule providing 
all of the expected data. The main anal ysis for all efficacy  endpoints will evaluate the 
primary  de fac to estimand of treatment policy  (effectiveness -type estimand): the mean 
difference between treatment groups for the time point of interest regardless of whether 
the participant remained on -treatment. This means that for an y given endpoint, all 
available da ta for a participant will be used including an y data that was collected after the 
participant was withdrawn from study  medication. Specific details for inclusion will be 
detailed in the reporting and anal ysis plan (RAP), but in general the minimum data 
required will be a baseline evaluation and at least one post -baseline evaluation. For the 
powered endpoints only , a secondary  de jure efficacy -type estimand will be evaluated by  
using onl y on-treatment data.
Endpoints relating to daily  diary  assessments will be calculated from all available data 
over the time period of interest . In addition to the weeks 1 -12 time period, smaller time 
periods will also be defined i n order to perform sensitivity  analy ses. H owever for any  
given time-period that is defined, no imp utations will be performed on missing dail y 
diary  data within that time period . Any defined time period for a diary  data endpoint will 
be considered missing if less than 2 day s (i.e., 24- hr periods) are recorded in that time 
period.
For the derivation of the percentage of s ymptom -free 24- hour periods, a given 24 -hour 
period will be considered as missing if both the day -time and night- time data are missing 
or if one is sy mptom -free but the other is missing. However, if either the day time or the 
night -time has s ymptoms then the 24- hour period will be considered not s ymptom -free. 
The same principals will be applied to the derivation of the percentage of rescue -free 24-
hour periods. 
Any tests for interactions will be 2 -sided at the 10% le vel of significance. In all cases, if 
any assumptions of the proposed method of analyses are not met, alternative methods of 
analyses will be used.
It is anticipated that a large number of centers will participate in the stud y. Therefore, it is 
likely  that many centers will enroll very small number of participants. Consequently , all 
centers within the same country  will be pooled. In addition, if there are an y countries 
enrolling very  small numbers in total (<12), these countries will be pooled with another 
country  within a similar geographical region. All amalgamations will be finalized and 
documented prior to unblinding the treatment codes. These amalgamations will be used 
wherever region is incorporated into the anal ysis.
2016N298634_04 CONFIDENTIA L
HZA107116
62Baseline values for each endpoint will be those used as appropriate from either Visit 2 or 
Visit 3 for clinic visit endpoints or derived from the last 7 day s of the run -in daily  diary  
prior to the randomisation of the patient.
12.3.3.1. Primary  Efficacy  Analyses
12.3.3.1.1. Primary Efficacy Analyses for 5 -17 Ye ars Old Population
To address the primary  effectiveness- type estimand, the primary  analy sis on the ITT (5-
17 Years Old) population will include data from all participants regardless of whether or 
not they  were on -treatment at the time of their week 12 seri al FEV 1measurements. 
To address the secondary efficacy -type estimand, the anal ysis will be repeated using onl y 
on-treatment data.
The primary  endpoint of weighted mean FEV 1(0-4 hours) at week 12 will be derived 
using the post -dose assessments (after 30 minutes and 1, 2, 3, 4 hours) with their actual 
times and using the pre -dose assessment as the 0 hour measurement. The weighted mean 
will be calculated as the average area under the curve using the trapezoidal rule, and 
dividing by  the relevant time interval (i.e. the time between the actual time of dose and 
the actual time of the last FEV 1measurement being used). 
The weighted mean will be anal ysed using an analy sis of covariance (ANCOVA) model 
with effects due to baseline pre-dose FEV 1, region, sex, age and treatment group. The 
adjusted means for each treatment and the estimated treatment differences for the 
treatment comparison will be presented together with 95% confidence intervals for the 
difference and a p- value for the treatment comparison.
12.3.3.1.2. Primary Efficacy Analyses for 5 -11 Years Old Population
To address the primary  effectiveness- type estimand, the primary  analy sis on the ITT (5-
11 Years Old) population will include all available AM PEF data from weeks 1 -12, 
regardless of whether the participant wa s still on -treatment at the time of the 
measurement.
To address the secondary efficacy -type estimand, the anal ysis will be repeated using onl y 
on-treatment data.
The primary  endpoint of change from baseline in AM PEF averaged over weeks 1 -12 will 
be calcul ated for each participant using onl y data that are from the first 84 calendar days 
after randomisation .
The primary  anal ysis will be performed using an ANCOVA model with effects due to 
baseline AM PEF, region, sex, age and treatment group. The adjusted mea ns for each 
treatment and the estimated treatment differences for the treatment comparison will be 
presented together with 95% confidence intervals for the difference and a p -value for the 
treatment comparison.
A sensitivity  anal ysis for the primary  effect iveness -type estimand will be performed 
including all data from weeks 1 -12 (regardless of treatment state). For this analy sis, the 
2016N298634_04 CONFIDENTIA L
HZA107116
63weeks 1 -12 time period will be split into 6 separate time periods: Weeks 1- 2, Weeks 3-4, 
Weeks 5- 6, Weeks 7- 8, Weeks 9 -10 and Weeks 11 -12. The data will then be anal ysed 
using a mixed model repeated measures (MMRM) model, which will allow for effects 
due to baseline AM PEF, region, sex, age, time period and treatment group. This model 
will also contain a time period -by-baseline interaction term and a time period -by-
treatment interaction term. Missing data are not implicitly  imputed in this anal ysis. 
However, all non -missing data for a participant will be used within the analy sis to 
estimate the average treatment effect over Weeks 1-12.
12.3.3.2. Secondary  Efficacy  Analyses
Change from Baseline in the Percentage of Rescue -free 24- Hour Periods for the 
ITT (5- 11 Years Old) Population
To address the primary  effectiveness- type estimand, the primary  analy sis on the ITT (5-
11 Years Old) population will include all available data from weeks 1 -12, regardless of 
whether the participant was still on -treatment at the time of the question.
To address the secondary efficacy -type estimand, the anal ysis will be repeated using onl y 
on-treatment data.
The powered secondary  endpoint of change from baseline in the percentage of rescue-
free 24 hour periods over weeks 1 -12 will be calculated for each participant using onl y 
data that are from the first 84 calendar day s after randomisation .
The primary  analysis will be performed using an ANCOVA model with effects due to 
baseline, region, sex, age and treatment group. The adjusted means for each treatment 
and the estimated treatment differences for the treatment comparison will be presented 
together with 95% confidence intervals for the difference and a p-value for the treatment 
comparison.
A sensitivity  anal ysis for the primary  effectiveness- type estimand will be performed 
including all data from weeks 1 -12 (regardless of treatment state). For this analy sis, the 
weeks 1 -12 time period will be split into 6 separate time periods: Weeks 1- 2, Weeks 3-4, 
Weeks 5- 6, Weeks 7- 8, Weeks 9 -10 and Weeks 11- 12. The data will then be anal ysed 
using a mixed model repeated measures (MMRM) model, which will allow for effec ts 
due to baseline, region, sex, age, time period and treatment group. This model will also 
contain a time period -by-baseline interaction term and a time period -by-treatment 
interaction term. Missing data are not implicitly  imputed in this analy sis. However, all 
non-missing data for a participant will be used within the anal ysis to estimate the average 
treatment effect over Weeks 1-12.
Change from Baseline in the Percentage of Rescue -free 24- Hour Periods for the 
ITT (5- 17 Years Old) Population
The change fr om baseline in the percentage of rescue- free 24 hour periods over weeks 1-
12 is a secondary  endpoint for the 5- 17 years old population and will be calculated for 
each participant using only  data that are from the first 84 calendar day s after 
2016N298634_04 CONFIDENTIA L
HZA107116
64randomisation .The primary  anal ysis will be performed using an ANCOVA model with 
effects due to baseline, region, sex, age and treatment group.
Change from Baseline in the Percentage of Symptom -free 24 -Hour Periods
The change from baseline in the percentage of s ymptom -free 24 hour periods over weeks 
1-12 will be calculated for each participant using only  data that are from the first 84 
calendar day s after randomisation . The primary  analy sis will be performed using an 
ANCOVA model with effects due to baseline, region, sex , age and treatment group.
Change from Baseline in A M FEV 1
Change from baseline in AM FEV 1at week 12 will be defined using the pre-dose FEV 1
assessment at the Week 12 clinic visit. Analy sis will be performed using an MMRM 
model, which will allow for effec ts due to baseline FEV 1, region, sex, age, visit and 
treatment group. This model will also contain a visit- by-baseline interaction term and a 
visit-by-treatment interaction term. Missing data are not implicitly  imputed in this 
analysis. However, all non- missing pre -dose data for a participant taken at scheduled 
visits 3, 4 and 5 (weeks 4, 8 and 12) will be used within the analy sis to estimate the week 
12 treatment effects.
Change from Baseline in A CQ-5
Change from baseline in ACQ- 5 at week 24 will be anal ysed using an MMRM model, 
which will allow for effects due to baseline, region, sex, age, visit and treatment group. 
This model will also contain a visit -by-baseline interaction term and a visit- by-treatment 
interaction term. Missing data are not implicitly  imputed in this analy sis. However, all 
non-missing data for a participant taken at scheduled visits 5 and 8 (weeks 12 and 24) 
will be used within the analy sis to estimate the week 24 treatment effects.
Weighted Mean FEV 1(0-4 hours) for 5 -11 Years Old Popu lation
Weighted mean FEV 1(0-4 hours) at week 12 is a secondary  endpoint for the 5 -11 years 
old population. I t will be anal ysed using an anal ysis of covariance (ANCOVA) model 
with effects due to baseline FEV 1, region, sex, age and treatment group. 
Change from Baseline in A M PEF for 5 -17 Years Old Population
The change from baseline in PM PEF over weeks 1- 12 is a secondary  endpoint for the 5-
17 years old population and will be calculated for each participant using only  data that 
are from the first 84 calendar day s after randomisation . The primary  anal ysis will be 
performed using an ANCOVA model with effects due to baseline, region, sex, age and 
treatment group.
Change from Baseline in PM PEF
The change from baseline in PM PEF over weeks 1- 12 will be calculat ed for each 
participant using onl y data that are from the first 84 calendar days after randomisation . 
The primary  anal ysis will be performed using an ANCOVA model with effects due to 
baseline, region, sex, age and treatment group.
2016N298634_04 CONFIDENTIA L
HZA107116
6512.3.3.3. Other A nalyses
The reporting and anal ysis of other endpoints as specified in the protocol will be provided 
in the RAP.
12.3.4. Interim A nalyses
There are no interim analy ses planned during this study .
2016N298634_04 CONFIDENTIA L
HZA107116
6613. REFERENCES
Fanta CH.  Asthma.  N Engl J Med. 2009;360(1):1002-14.
Global I nitiativ e for Asthma (GINA).  Global strategy  for asthma management and 
prevention 2015. Available at: www.ginasthma.org.
Global I nitiative for Asthma (GINA).  Global strategy  for asthma management and 
prevention 2016. Available at: http://ginasthma.org/2016 -gina-report- global -strategy -for-
asthma -management -and-prevention.
Investigator’s Brochure for FF, GlaxoSmithKline Document Number: 
GM2004/00283/11; August 2016.
Investigator’s Brochure for FF/VI, GlaxoSmithKline Document Number: 
RM2008/00012/09; September 2016.
Juniper EF, Bousquet J, Abetz L , Bateman ED; GOAL Committee. I dentify ing 'well-
controlled' and 'not well -controlled' asthma using the Asthma Control Questionnaire. 
Respir Med 2006;100:616-621.
Juniper EF, Svensson K, Mörk AC, Ståhl E. Measurement properties and interpretation of 
three shortened versions of the asthma control questionnaire. Respir Med 2005 b;99:553 -
558.
Juniper EF, Svensson K, Mörk AC, Ståhl E. Modification of the Asthma Quality  of Life 
Questionnaire (standardi sed) in patients 12 y ears and older. Health and Quality of Life 
Outcomes 2005 a;3:58.
Kelly  HW, et al. Effects of inhaled corticosteroids in childhood on adult height. N Engl J 
Med 2012;367: 904-12.
National Institutes of Health (NIH).  Guidelines for the D iagnosis and Management of 
Asthma - Expert Panel Report 3, 2007.  U.S. Department of Health and Human Services, 
Bethesda, MD; 2007.  NIH Publication No. 07 -4051.
Pedersen S, O'By rne P.  A comparison of efficacy and safet y of inhaled corticosteroids in 
asthma.  Allergy . 1997;52(39 Suppl):1-34.
Peters SP, Bleeker ER, Canonica GW, Park YB, Ramirez R, et al.  Serious asthma events 
with budesonide plus formoterol vs. budesonide alone.  N Engl J Med 2016;375:850 -60.
Price D, Robertson A, Bullen K, Rand C, Horne R , Standinger H.  Improved adherence 
with once -daily versus twice -daily dosing of mometasone furoate administered via a dry  
powder inhaler:  a randomized open- label study . BMC Pulmonary  Medicine. 2010;10:1 -
9.
2016N298634_04 CONFIDENTIA L
HZA107116
67Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi -ethnic 
reference values for spirometry for the 3 –95-yr age range: the global lung function 2012 
equations. Eur Respir J 2012; 40: 1324 –1343.
Stempel DA, Raphiou I , Kral KM, Yeakey  A, Emmett AH, et al. Serious asthma events 
with fluticasone plus salmeterol versus fluticasone alone. N Engl J Med 2016a;374:1822 -
30.
Stempel DA, Szefler S, Pedersen S, Zeiger, RS, Yeakey  AM, et al.  Safet y of adding 
salmeterol to fluticasone propionate in children with asthma.  N Engl J Med 
2016b;375:8 40-9.
Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat CA, Swensen A, Duh MS. 
Treatment of COPD: relationships between daily  dosing frequency , adherence, resource 
use, and costs. Respir Med 2011;105:435-44.
Wells KE, Peterson EL , Ahmedani BK, et al. Real- world effects of once vs greater dail y 
inhaled corticosteroid dosing on medication adherence. Ann Allergy  Asthma I mmunol. 
2013 Sep;111(3):216-20.
Zhang L, Prietsch SOM.  Effect of inhaled corticosteroids on linear growth in children 
with persistent asthma.  Paediatric Respir Rev. 2014;15(4):322– 4.
2016N298634_03 CONFIDENTIA L
HZA107116
6814. APPENDICES
14.1. Appendix 1: A bbreviations and Trademarks
ACQ Asthma Control Questionnaire
AE Adverse event
AM Ante meridiem (morning)
ANCOVA Analy sis of covariance
ATS American Thoracic Society
BID Twice dail y
BMI Body Mass Index
cACT Childhood asthma control test
CDC Centers for Disease Control and Prevention
CI Confidence interval
CONSORT Consolidated Standards of Reporting Trials
COPD Chronic obstructive pulmonary  disease
CRF Case report form
CRO Contract Research Organisation
CYP3A4 Cytochrome P450 3A4
dl Decilitre
DNA Deox yribonucleic acid
ECG Electrocardiogram
eCRF Electronic case report form
EMA European Medicines Agency
ERS European Respiratory  Society
ETD Early treatment discontinuation
EW Early withdrawal
FDA Food and Drug Administration
FEV 1 Forced expiratory  volume in 1 second
FF Fluticasone furoate
FF/V I Fluticasone furoate/vilanterol
FP Fluticasone propionate
FRP Females of reproductive potential
FU Follow -up
GCSP Global Clinical Safety  and Pharmacovigilance
GINA Global I nitiative for Asthma
GSK GlaxoSmithKline
HPA Hypothalamic -pituitary  adrenal axis
ICF Informed consent document
ICS Inhaled corticosteroid
IEC Independent ethics committee
IgE Immunoglobulin E
IL Interleukin
IRB Institutional review board
ITT Intent -to-treat
2016N298634_03 CONFIDENTIA L
HZA107116
69IVRS/I WRS Interactive Voice Response System/Interactive Web Response 
System
L/Min Litre per Minute
LABA Long -acting beta agonist
LOCS Lens opacities classification sy stem
LTRA Leukotriene receptor antagonist
mcg Microgram
MDI Metered dose inhaler
mol/L Mole per Litre
MMRM Mixed model repeated measures
MSDS Material Safet y Data Sheet
msec Millisecond
NIH National Institutes of Health
PDCO Paediatric Committee
PEF Peak expiratory  flow
PIP Paediatric investigational plan
PM Post meridiem (evening)
QTcB QT interval corrected for heart rate according to Bazett’s formula
QTcF QT interval corrected for heart rate according to Fridericia’s formula
RAP Reporting and Anal ysis Plan
SABA Short -acting beta agonist
SDS Standard Deviation Score
SAE Serious adverse event
SAMA Short -acting muscarinic antagonist
SAWP Scientific Advice Working Pa rty
SOA Schedule of activities
SRM Study  reference manual
SUSAR Suspected unexpected serious adverse reactions
TC Telephone call
V Visit
VI Vilanterol
WOCBP Woman of Childbearing Potential
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by the 
GlaxoSmithKline group of companies
ELLIPTA Combivent
NUCALA Dulera
RELVAR Symbicort
SERETIDE Xolair
2016N298634_03 CONFIDENTIA L
HZA107116
7014.2. Appendix 2: Study  Governance Considerations
Regulatory  and Ethical Considerations
This study  will be conducted in accordance with the protocol and with:
Consensus ethical principles derived from international guidelines 
including the Declaration of Helsinki and Council for International 
Organizations of Medical Sciences (CIOMS) International Ethical 
Guidelines
Applicable International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use ( ICH)
Good Clinical Practice (GCP) Guidelines
Applicable laws and regulations
The protocol, protocol amendments, I CF, Investigator Brochure, and other 
relevant documents (eg, advertisements) must be submitted to an I RB/IEC by  
the investigator and reviewed and approved b y the I RB/IEC before the study  is 
initiated. 
Any amendments to the protocol will require IEC/I RB approv al before 
implementation of changes made to the stud y design, except for changes 
necessary  to eliminate an immediate hazard to study participants. 
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/IEC 
annually  or more frequently  in accordance with the requirements, policies, 
and procedures established by  the IRB/ IEC
Notify ing the IRB/IEC of SAE or other significant safet y findings as 
required b y IRB/IEC procedures
Providing oversight of the conduct of the study  at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European 
regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local regulations
Financial Disclosure
Investigator s and sub-investigators will provide the sponsor with sufficient, accurate 
financial information as requested to allow the sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible for providing information on financial interests during the 
course of the stud y and for 1 y ear after completion of the study .
Informed Consent Process
The investigator or his/her representative will explain the nature of the st udy to 
the participant or his/her legally  authorized representative and answer all 
questions regarding the study . 
2016N298634_03 CONFIDENTIA L
HZA107116
71Participants must be informed that their participation is voluntary . Participants 
or their legall y authorized representative will be require d to sign a statement of 
informed consent that meets the requirements of 21 CFR 50, local regulations, 
ICH guidelines, Health Insurance Portability  and Accountability  Act (HI PAA) 
requirements, where applicable, and the IRB/IEC or study  center. 
The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study  and the date the written 
consent was obtained. The authorized person obtaining the informed consent 
must also sign the I CF.
Partic ipants must be re- consented to the most current version of the ICF(s) 
during their participation in the study . 
A cop y of the ICF(s) must be provided to the participant or the participant’s 
legally  authorized representative. 
Participants who are rescreene d are required to sign a new ICF.
Data Protection
Participants will be assigned a unique identifier by  the sponsor. Any participant 
records or datasets that are transferred to the sponsor will contain the identifier 
only; participant names or any  informat ion which would make the participant 
identifiable will not be transferred. 
The participant must be informed that his/her personal study -related data will be 
used by  the sponsor in accordance with local data protection law. The level of 
disclosure must al so be explained to the participant. 
The participant must be informed that his/her medical records may  be examined 
by Clinical Qualit y Assurance auditors or other authorized personnel appointed 
by the sponsor, b y appropriate IRB/IEC members, and by  inspect ors from 
regulatory  authorities.
Committees Structure
Not applicable.
Publication Policy
The results of this study  may  be published or presented at scientific meetings. If 
this is foreseen, the investigator agrees to submit all manuscripts or abstracts to 
the sponsor before submission. This allows the sponsor to protect proprietary  
information and to provide comments.
The sponsor will comply  with the requirements for pu blication of study  results. 
In accordance with standard editorial and ethical practice, the sponsor will 
generall y support publication of multicentre studies only  in their entiret y and not 
as individual site data. In this case, a coordinating investigato r will be 
designated b y mutual agreement.
2016N298634_03 CONFIDENTIA L
HZA107116
72Authorship will be determined by  mutual agreement and in line with 
International Committee of Medical Journal Editors authorship requirements.
Dissemination of Clinical Study  Data
Where required b y applicable regul atory  requirements, an investigator signatory  will be 
identified for the approval of the clinical study  report.  The investigator will be provided 
reasonable access to statistical tables, figures, and relevant reports and will have the 
opportunity  to revie w the complete study  results at a GSK site or other mutually -
agreeable location.
GSK will also provide the investigator with the full summary  of the stud y results.  The 
investigator is encouraged to share the summary  results with the study  subjects, as 
appropriate.
GSK will provide the investigator with the randomisation codes for their site only  after 
completion of the full statistical analy sis.
The procedures and timing for public disclosure of the results summary  and for 
development of a manuscript fo r publication will be in accordance with GSK Policy .
Data Quality  Assurance
All participant data relating to the stud y will be recorded on printed or electronic 
CRF unless transmitted to the sponsor or designee electronically  (eg, laboratory  
data). The investigator is responsible for verify ing that data entries are accurate 
and correct b y physically or electronically signing the CRF. 
The investigator must maintain accurate documentation (source data) that 
supports the information entered in the CRF. 
The investigator must permit study -related monitoring, audits, IRB/IEC review, 
and regulatory  agency  inspections and provide direct access to source data 
documents. 
The sponsor or designee is responsible for the data management of this study  
including qualit ychecking of the data. 
Study  monitors will perform ongoing source data verification to confirm that 
data entered into the CRF b y authorized site personnel are accurate, complete, 
and verifiable from source documents; that the safety  and rights of particip ants 
are being protected; and that the study is being conducted in accordance with the 
currentl y approved protocol and an y other stud y agreements, ICH GCP, and all 
applicable regulatory  requirements. 
Records and documents, including signed ICF, pertaining to the conduct of this 
study  must be retained by the investigator for 25years after stud y completion 
unless local regulations or institutional policies require a longer retention period. 
No records may  be destroy ed during the retention period without the written 
approval of the sponsor. No records may  be transferred to another location or 
party  without written notification to the sponsor. 
2016N298634_03 CONFIDENTIA L
HZA107116
73Source Documents
Source documents provide evidence for the existence of the participant and 
substantiate the integri ty of the data collected. Source documents are filed at the 
investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from 
source documents must be consistent with the source documents or the 
discrepancies must be explained. The investigator may  need to request previous 
medical records or transfer records, depending on the study . Also, current 
medical records must be available.
Definition of what constitutes source data can be found in the source data 
agreement or source da ta verification form .
Study and Site Closure
GSK or its designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of GSK. Study  sites will be closed upon study  
completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time, provided there is reasonable 
cause and su fficient notice is given in advance of the intended termination.
Reasons for the earl y closure of a stud y site b y the sponsor or investigator may include 
but are not limited to:
Failure of the investigator to comply  with the protocol, the requirements of t he 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of participants b y the investigator
Discontinuation of further study  treatment development
2016N298634_03 CONFIDENTIA L
HZA107116
7414.3. Appendix 3: Adverse Events: Definitions and Procedures for
Recording, Evaluating, Follow -up, and Reporting
Definition of A E
AE Definition
An AE is an y untoward medical occurrence in a clinical study participant, 
temporally  associated with the use of a stud ytreatment, whether or not considered 
related to the stud y treatment.
NOTE: An AE can therefore be any unfavorable and unintended sign (including 
an abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) 
temporally  associated with the use of a stud y treatment.
Events Meeting the AE Definition 
Any abnormal laboratory test results (hematology , clinical chemistry , or 
urinaly sis) or other safety  assessments (e .g.ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically  
significant in the medical and scientific judgment of the investigator (ie, not 
related to progression of underly ing disease).
Exacerbatio n of a chronic or intermittent pre -existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y treatment administration even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication. Overdose per se will not be report ed as an 
AE/SAE unless it is an intentional overdose taken with possible 
suicidal/self-harming intent. Such overdoses should be reported regardless of 
sequelae.
"Lack of efficacy " or "failure of expected pharmacological action" per se will not 
be reported as an AE or SAE. Such instances will be captured in the efficacy 
assessments. However, the signs, s ymptoms, and/or clinical sequelae resulting 
from lack of efficacy  will be reported as AE or SAE if they  fulfill the definition of 
an AE or SAE.
2016N298634_03 CONFIDENTIA L
HZA107116
75Events N OTMeeting the AE Definition 
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  
the investigator to be more severe than expected for the participant’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) 
present or detected at the start of the study  that do not worsen.
Definition of SA E
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospitalization for signs/symptoms of the disease under study , 
death due to progression of disease).
A SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, 
which hy potheticall y might have caused death, if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalization signifies that the participant has been detained (usually 
involving at least an overnight stay ) at the hospital or emergency  ward for observation 
and/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting. Complications that occur during hospitalization are AE. If a 
complication prolongs hospitalization or fulfills any other serious criteria, the event is 
serious. When in doubt as to whether “hospitalization” occurred or was necessary , the 
AE should be considered serious.
Hospitalization for elective treatment of a pre-existing condition that did not worsen 
from baseline is not considered an AE.
2016N298634_03 CONFIDENTIA L
HZA107116
76d.Results in persistent disability/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicate d headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle) which may  interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Other situation s:
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediatel y life-threatening or result in death or hospitalization but 
may jeopardiz e the participant or may  require medical or surgical intervention to 
prevent one of the other outcomes listed in the above definition. These events 
should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospitalization, or development of 
drug dependency  or drug abuse.
Recording A E and SA E
AE and SAE Recording
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospital progress notes, laboratory, and diagnostics reports) 
related to the event.
The investigator will then record all relevant AE/SAE information in the CRF.
It is notacceptable for the investigator to send photocopies of the participant’s 
medical records to GSK in lieu of completion of the GSK /AE/SAE CRF page.
There may  be instances when copies of medical records for certain cases are 
requested b y GSK . In this case, all participant identifiers, with the exception of 
the participant number, will be redacted on the copies of the medical records 
before submission to GSK .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptom s, and/or other clinical information. Whenever possible, the diagnosis 
(not the individual signs/sy mptoms) will be documented as the AE/SAE.
2016N298634_03 CONFIDENTIA L
HZA107116
77Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: An event that is easily  tolerated by  the participant, causing minimal 
discomfort and not interfering with every day activities.
Moderate: An event that causes sufficiently  discomfort and int erferes with normal 
every day activities.
Severe: An event that prevents normal every day activities. An AE that is assessed 
as severe should not be confused with an SAE. Severe is a category  utilized for 
rating the intensity of an event; and both AE and SAE can be assessed as severe.
An event is defined as ‘serious’ when it meets at least 1 of the predefined 
outcomes as described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y treatment 
and each occurrence of each AE/SAE.
A "reasonable possibility " of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  treatment 
administration will be considered and investigated.
The investigator will also consult the Investigator’s Brochure and/or Product 
Information, for marketed products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical note s that 
he/she has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to GSK . However, it is very 
important that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to GSK .
The investigator may  change his/her opinion of causality  in light of follow -up 
information and send an SAE follow- up report wi th the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
2016N298634_03 CONFIDENTIA L
HZA107116
78Follow -up of AE and SAE
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  GSK 
to elucidate the nature and/or causalit y of the AE or SAE as fully as possible. This 
may include additional laboratory  tests or investigations, histopathological 
examinations, or c onsultation with other health care professionals.
If a participant dies during participation in the study or during a recognized 
follow -up period, the investigator will provide GSK with a cop y of an y post -
mortem findings including histopathology . 
New or updated information will be recorded in the originally completed CRF.
The investigator will submit any  updated SAE data to t GSK within 24 hours of 
receipt of the information.
Reporting of SA E to GSK
SAE Reporting to GSK via Electronic Data Collection Tool
The primary  mechanism for reporting SAE to GSK will be the electronic data 
collection tool.
If the electronic s ystem is unavailable for more than 24 hours, then the site will 
use the paper SAE data collec tion tool (see next S ection).
The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
After the stud y is completed at a given site, the electronic data collection tool will 
be taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study participant or receives 
updated data on a previously  reported SAE after the electronic data collection tool 
has been taken off -line, then the site can report this information on a paper SAE 
form (see next S ection) or to the medical monito rby telephone.
Contacts for SAE reporting can be found in theSRM .
SAE Reporting to GSK via Paper CRF
Facsimile transmission of the SAE paper CRF is the preferred method to transmit 
this information to the medical monitor .
In rare circumstances and in the absence of facsimile equipment, notification by  
telephone is acceptable with a cop y of the SAE data collection tool sent by 
overnight mail or courier service.
2016N298634_03 CONFIDENTIA L
HZA107116
79Initial notification via telephone does not replace the need for th e investigator to 
complete and sign the SAE CRF pages within the designated reporting time 
frames.
Contacts for SAE reporting can be found in theSRM .
2016N298634_03 CONFIDENTIA L
HZA107116
8014.4. Appendix 4: Contraceptive Guidance and Collection of 
Pregnancy  Information
Definitions
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post -menopausal 
unless permanentl y sterile (see below) .
Women in the following categories are not considered WOCBP
1.Premenarchal
2. P remenopausal female with ONE of the following:
Documented h ysterectomy
Documented bilateral salpingectomy
Documented bilateral oophorectom y
Note:  Documentation can come from the site personnel’s: review of participant’s 
medical records, medical examination, or medical history  interview.
3. P ostmenopausal female
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. A high follicle stimulating hormone (FSH) level in 
the postmenopausal range may  be used to confirm a postmenopausal state in 
women not using hormonal contraception or hormonal replacement therapy  
(HRT). However, in the absence of 12 months of amenorrhea, a single FSH 
measurement is insufficient. 
Females on HRT and whose menopausal status is in doubt will be required to 
use o ne of the non -hormonal highl y effective contraception methods if they wish 
to continue their HRT during the stud y. Otherwise, they  must discontinue HRT 
to allow confirmation of postmenopausal status before study  enrollment.
Contraception Guidance
Female p articipants
Female participants of childbearing potential are eligible to participate if they  agree to 
use a highly effective method of contraception consistently  and correctly  as described in 
Table 5. 
2016N298634_03 CONFIDENTIA L
HZA107116
81Table 5 Highly  Effective Contraceptive Methods
Highly Effective Contraceptive Methods That Are User Dependent a
Failure rate of <1%  per year when used consistently and correctly. 
Combined (estrogen -and progestogen -containing ) hormonal contraception associated with 
inhibition of ovulationb
oral
intravaginal 
transdermal 
Progestogen -only hormonal contraception associated with inhibition of ovulationb
injectable 
Highly Effective Methods That Are User Independent 
Implantable progestogen -only hormonal contraception associated with inhibition of 
ovulationb
Intrauterine device (IUD)
Intrauterine hormone- releasing system (IUS)
bilateral tubal occlusion
Vasectomized partner 
(A vasectomized partner is a highly effective contraception method provided that the partner is 
the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed .  If 
not, an additional highly effective method of contraception should be used. )
Sexual abstinence 
(Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study drug. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the study 
and the preferred and usual lifestyle of the participant.)
NOTES: 
a. Typical use failure rates may differ from tho se when used consistently and correctly. Use should be consistent 
with local regulations regarding the use of contraceptive methods for participants inclinical studies. 
b. Hormonal contraception may be susceptible to interaction with the study drug, which may reduce the efficacy of 
the contraceptive method. In this case two highly effective methods of contraception should be utilized during the 
treatment period and for at least X, corresponding to time needed to eliminate study treatment plus 30 days for 
study treatments with genotoxic potential  after the last dose of study treatment 
Pregnancy  Testing
WOCBP should only  be included after a confirmed menstrual period and a negative 
highl y sensitive urine pregnancy  test 
2016N298634_03 CONFIDENTIA L
HZA107116
82Additional pregnancy  testing is not required during the treatment period 
corresponding to time needed to eliminate study  treatment plus 3 0 day s for study  
treatments with genotoxic potential  after the last dose of study  treatment and as 
required locally  
Pregnancy  testing will be performed whenever a menstrual cy cle is missed or when 
pregnancy  is otherwise suspected 
Pregnancy  testing, with a sensitivity  of 5, 10, 25 mIU /mL will be performed and 
assay ed in a certified laboratory  OR and assay ed in the central laboratory  OR using 
the test kit provided by  the central laboratory  / provided by  the sponsor /approved by  
the sponsor and in accordanc e with instructions provided in its package insert   
Collection of Pregnancy  Information
Female Participants who become pregnant
Investigator will collect pregnancy  information on any  female participant, who 
becomes pregnant while participating in this study. 
Information will be recorded on the appropriate form and submitted to GSK within 
24 hours of learning of a participant's pregnancy . 
Participant will be followed to determine the outcome of the pregnancy . The 
investigator will collect follow up information on participant and neonate, which will 
be forwarded to GSK Generall y, follow -up will not be required for longer than 6 to 
8weeks bey ond the estimated delivery  date.  
Any termination of pregnancy  will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure. 
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complication or elective termination of a pregnancy will be reported as an AE or 
SAE. 
A spontaneous abortion is alway s considered to be an SAE and will be reported as 
such.  
Any SAE occurring as a result of a post -study  pregnancy  which is considered 
reasonabl y  related to the study  treatment by  the investigator, will be reported to GSK 
as described in Appendix 3. While the investigator is not obligated to actively  seek 
this information in former study  participants, he or she may  learn of an SAE through 
spontaneous reporting. 
Any female participant who becomes pregnant while participating will discontinue 
study  treatment
2016N298634_03 CONFIDENTIA L
HZA107116
8314.5. Appendix 5: Genetics
USE/ANALYSIS OF DNA
Genetic variation may  impact a participant’s response to therap y, susceptibility , 
severit y and progression of disease. Variable response to therapy  may  be due to 
genetic determinants that impact drug absorption, distribution, metabolism, and 
excretion; me chanism of action of the drug; disease etiology ; and/or molecular 
subty pe of the disease being treated. Therefore, where local regulations and 
IRB/IEC allow, a saliva sample will be collected for deox yribonucleic acid ( DNA)
analysis.
DNA samples will be u sed for research related to [ FF/V Ior FF ] or [ asthma ] and 
related diseases. They  may  also be used to develop tests/assay s including diagnostic 
tests) related to [ FF/V Ior FF ] (or study  treatments of this drug class), and [ asthma ]. 
Genetic research may  consist of the analy sis of one or more candidate genes or the 
analysis of genetic markers throughout the genome [or anal ysis of the entire genome] 
(as appropriate) .
DNA samples will be analy zed if it is hy pothesized that this may  help further 
understand th e clinical data. 
The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality . 
The samples will be retained while research on [ FF/VI or FF ] (or study  treatments of 
this class) or [ asthma ] continues bu t no longer than [ 15] years or other period as per 
local requirements.
2016N298634_03 CONFIDENTIA L
HZA107116
8414.6. Appendix 6: Liver Safety : Required A ctions and Follow -up 
Assessments
Phase III -IV liver chemistry stopping and increased monitoring criteria have been 
designed to assure participant saf ety and evaluate liver event etiology (in alignment with 
FDA premarketing clinical liver safet y guidance.  
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf ).
Phase III -IV liver chemistry stopping criteria a nd required follow up assessments 
Liver Chemistry Stopping Criteria 
ALT- absolute ALT  8xULN
ALT Increase ALT  5xULN but <8xULN  persists for 2 weeks
ALT  3xULN but <5xULN  persists for 4 weeks
Bilirubin1, 2ALT  3xULN andbilirubin 2xULN (>35% direct bilirubin) 
INR2ALT  3xULN andINR>1.5, if INR measured
Cannot 
MonitorALT  5xULN but <8xULN and cannot be monitored weekly for  2 weeks
ALT  3xULN but <5xULN and cannot be monitored weekly for  4 weeks
Symptomatic3ALT   3xULN associated with symptoms (new or worsening) believed to be 
related to  liver injury or hypersensitivity
Required Actions and Follow up Assessments 
Actions Follow Up Assessments
Immediately discontinue  study treatment 
Report the event to GSK within 24 hours
Complete the liver event CRF and complete 
an SAE data collection tool if the event also 
meets the criteria for an SAE2
Perform liver event follow up assessments 
Monitor the participant until liver chemistries 
resolve, stabilize, or return to within 
baseline (see MONITORING below)
Do not restart/rechallenge participant with 
study treatment unless allowed per protocol Viral hepatitis serology4
Obtain INR and recheck with each liver 
chemistry assessment until the 
transaminases values show downward 
trend
Only in those with underlying chronic 
Hepatitis B at study entry (identified by 
positive Hepatitis B surface antigen) 
quantitative Hepatitis B DNA and 
Hepatitis delta antib ody5.
Obtain blood sample for pharmacokinetic 
(PK) analysis, within insert time interval 
recommended by clinical 
2016N298634_03 CONFIDENTIA L
HZA107116
85Liver Chemistry Stopping Criteria 
and GSK Medical Governance approval is 
granted .
If restart/rechallenge not  allowed or not 
granted , permanently discontinue s tudy 
treatment and continue participant in the 
study for any protocol specified follow up 
assessments
MONITORING:
For bilirubin or INR criteria:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow up assessments within  24 
hrs
Monitor participants twice weekly until liver 
chemistries resolve, stabilize or return to 
within baseline
A specialist or hepatology consultation is 
recommended
For All other criteria:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow up assessments within  
24-72 hrs 
Monitor participants weekly until liver 
chemistries resolve, stabilize or return to 
within baselinepharmacokinetics representative after 
last dose6
Serum creatine phosphokinase (CPK) 
and lactate dehydrogenase (LDH).
Fractionate bilirubin, if total 
bilirubin 2xULN
Obtain complete blood count with 
differential to assess eosinophilia
Record the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity, on the AE report form
Record use of concomitant medications 
on the concomitant medications report 
form including acetaminophen, herbal 
remedies, other over the counter 
medications .
Record alcohol use on the liver event 
alcohol intake case report form (CRF) 
page
For bilirubin or INR criteria:
Anti-nuclear antibody, anti-smooth 
muscle antibody, Type 1 anti- liver kidney 
microsomal antibodies, and quantitative 
total immunoglobulin G (IgG) or gamma 
globulins.
Serum acetaminophen adduct high 
performance liquid chromatography 
(HPLC) assay (quantifies potential 
acetaminophe n contribution to liver injury 
in participants with definite or likely 
acetaminophen use in the preceding 
week [ James , 2009]). NOTE: not 
required in China
Liver imaging (ultrasound, magnetic 
resonance, or computerised tomography) 
and /or liver biopsy to evaluate liver 
disease; complete Liver Imaging and/or 
Liver Biopsy CRF forms.
2016N298634_03 CONFIDENTIA L
HZA107116
861. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study treatment for that participant if ALT 3xULN andbilirubin 2xULN. 
Additiona lly, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary 
bilirubin on dipstick , indicating direct bilirubin elevations and suggesting liver injury. 
2. All events of ALT 3xULN andbilirubin  2xULN (>35% direct bil irubin) or ALT 3xULN andINR>1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis) ; INR measurement is not required and the threshold value stated 
will not apply to participants receiving anticoagulants
3. New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, or jaundice) or believed to be related to hypersensiti vity (such as fever, rash or 
eosinophilia)   
4. Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen (HbsAg) and Hepatitis B Core Antibody (IgM); 
Hepatitis C RNA; Cytomegalovirus IgM antibody;  Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, 
obtain heterophile antibody or monospot testing);  Hepatitis E IgM antibody 
5. If Hepatitis delta antibody assay cannot be performed,, it can be replaced with a PCR of Hepatitis D RNA virus 
(where needed) [ Le Gal , 2005].
6. PK sample may not be required for participants known to be receiving placebo or non -GSK comparator 
treatments.  Record the date/time of the PK blood sample draw and the date/time of the last dose of study 
treatment prior to PK blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the 
participant’s best approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot 
be col lected in the time period indicated above, do not obtain a PK sample. Instructions for sample handling and 
shipping are in the SRM .
Phase III -IV liver chemistry increased monitoring criteria with continued therapy
Liver Chemistry Increased Monitoring Crit eria – Liver Monitoring Event
Criteria Actions
ALT  5xULN and <8xULN and
bilirubin <2xULN without symptoms 
believed to be related to liver injury or 
hypersensitivity, andwho can be 
monitored weekly for 2 weeks.
OR
ALT  3xULN and <5xULN and
bilirubin <2xULN without symptoms 
believed to be related to liver injury or 
hypersensitivity, andwho can be 
monitored weekly for 4 weeks.Notify the GSK medical monitor within 24 hours
of learning of the abnormality to discuss 
participant safety. 
Participant can continue study treatment 
Participant must return weekly for repeat liver 
chemistries (ALT, AST, alkaline phosphatase, 
bilirubin) until they resolve, stabilise or return to 
within baseline 
If at any time participant meets the liver chemist ry 
stopping criteria, proceed as described above
If ALT decreases from ALT 5xULN and <8xULN 
to ≥3xULN but <5xULN, continue to monitor liver 
chemistries weekly. 
If, after 4 weeks of monitoring, ALT <3xULN and 
bilirubin <2xULN, monitor participants twice 
monthly until liver chemistries normalize or return 
to within baseline.
2016N298634_03 CONFIDENTIA L
HZA107116
87References
James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee 
WM. Pharmacokinetics of Acetaminophen -Adduct in Adults with Acetaminophen 
Overdose and A cute Liver Failure. Drug Metab Dispos 2009; 37:1779 -1784.
Le Gal F, Gordien E, Affolabi D, Hanslik T, Alloui C, Dény P, Gault E.  Quantification 
of Hepatitis Delta Virus RNA in Serum by  Consensus Real -Time PCR I ndicates 
Different Patterns of Virological Re sponse to Interferon Therapy  in Chronically  Infected 
Patients.  J Clin Microbiol. 2005;43(5):2363– 2369. 
2016N298634_03 CONFIDENTIA L
HZA107116
8814.7. Appendix 7: A Es, ADEs, SA Es, SA DEs, USA DEs and Device 
Deficiencies: Definition and Procedures for Recording, 
Evaluating, Follow -up, and Reporting in M edical Device 
Studies
The definitions and procedures detailed in this appendix are in accordance with 
ISO 14155 and European Medical Device Regulation (MDR) 2017/745 for 
clinical device research (if applicable). 
Both the investigator and the sponsor will comply  with all local medical device 
reporting requirements for medical devices.
The detection and documentation procedures described in this protocol apply  to 
all GSK medical devices provided for use in the study  (see Section 9.1.1. for the 
list of GSK medical devices).
14.7.1. Definition of Medical Device A E and ADE
Medical Device AE and ADE Definition 
An AE is an y untoward medical occurrence, in a clinical study  participant, users, 
or other persons, temporally  associated with the use of study  intervention whether 
or not considered related to the investigational medical device. An AE can 
therefore be an y unfavorable and unintended sign (including an abnormal 
laboratory  finding), s ymptom, or disease (new or exacerbated) temporall y 
associated with the use of an investigational medical device. This definition 
includes events related to the investigational medical device or comparator and 
events related to the pro cedures involved.
An adverse device effect (ADE) is  an AErelated to the use of an investigational 
medical device. This definition includes any  AEresulting from insufficient or 
inadequate instructions for use, deplo yment, implantation, installation, or 
operation, or an y malfunction of the investigational medical device as well as an y 
event resulting from use error or from intentional misuse of the investigational 
medical device.
14.7.2. Definition of Medical Device SA E, SA DE and USA DE
AMedical Device SAE is any serious adverse event that:
g.Led todeath 
h. Led to serious deterioration in the health of the participant, that either resulted in:
A life -threatening illness or injury . The term ‘life -threatening' in the definition 
of ‘serious' refers to an event in which the participant was at risk of death at 
the time of the event. It does not refer to an event, which hy potheticall y might 
have caused death, if it were more severe .
2016N298634_03 CONFIDENTIA L
HZA107116
89A permanent impairment of a bod y structure or a body function .
Inpatient or prolonged hospitalization . Planned hospitalization for a pre-
existing condition, or a procedure required b y the protocol, without serious 
deterioration in health, is not considered an SAE .
Medical or surgical intervention to prevent life- threatening illness or injur y or 
permanent impairment to a body  structure or a body  function
i.Ledto fetal distress, fetal death or a congenital abnormality  or birth defect
j.Is a suspected transmission of an y infectious agent via a medicinal product
SADE definition
A SADE is defined as an adverse device effect that has resulted in an y of the 
consequences characteristic of a serious adverse event.
Any device deficiency  that might have led to an SAE if appropriate action had not 
been taken, intervention had not occurred, or circ umstances had been less fortunate.
Unanticipated SADE (USADE )definition
AnUSADE (also identified as UADE in US Regulations 21 CFR 813.3), is a 
serious adverse device effect thatby its nature, incidence, severit y or outcome has 
not been identified in the current version of the risk anal ysis report (see Section
3.3).
14.7.3. Definition of Device D eficiency
Device Deficiency Definition
A device deficiency  is an inadequacy  of a medical device with respect to its 
identity , quality , durability , reliability , safet y, or performance. Device deficiencies 
include malfunctions, use errors, and information supplied by  the manufacturer.
14.7.4. Recording and Follow -Up of A E and/or SA E and Dev ice 
Deficiencies
AE, SAE and Device Deficiency Recording
When an AE/SAE/device deficiency  occurs, it is the responsibility  of the 
investigator to review all documentation (e.g., hospital progress notes, laboratory  
reports, and diagnostics reports) related to the event.
The investigator will then record all relevant AE/SAE/device deficiency  
information in the participant’s medical records, in accordance with the 
investigator ’s normal clinical practice ,and on the appropriate form.
2016N298634_03 CONFIDENTIA L
HZA107116
90It is notacceptable for the investigator to send photocopies of the participant’s 
medical records to the CRO in lieu of completion of the CRO /AE/SAE/device 
deficiency  form .
There may  be instances when copies of medical records for certain cases are 
requested b y the CRO . In this case, all participant identifiers, with the exception of 
the participant number, will be redacted on the copies of the medical records 
before submissi on to the CRO .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis 
(not the individual signs/sy mptoms) will be documented as the AE/SAE.
For devic e deficiencies, it is very  important that the investigator describes any  
corrective or remedial actions taken to prevent recurrence of the deficiency .
oA remedial action is an y action other than routine maintenance or servicing of 
a medical device where suc h action is necessary  to prevent recurrence of a 
device deficiency . This includes any  amendment to the device design to 
prevent recurrence.
Assessment of Intensity
The investigator will make an assessment of intensity  for each AE/SAE/device 
deficiency  reported during the study  and assign it to one of the following 
categories: 
Mild: An event that is easily  tolerated by  the participant, causing minimal 
discomfort and not interfering with every day activities.
Moderate: An event that causes sufficient discomfort and interferes with normal 
every day activities.
Severe: An event that prevents normal every day activities. An AE that is assessed 
as severe should not be confuse d with a nSAE. Severe is a category  used for rating 
the intensity  of an event; both AEs and SAEs can be assessed as severe.
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes 
as described in the definition of an SAE, not when it is rated as severe.
Other measures to evaluate AEs and SAEs may  be utilized (e.g ., National Cancer 
Institute Common Terminology  Criteria for Adverse Events [NCI -CTCAE]).
Assessment of Causality
The investigator is obligated to assess the relationship between study  intervention 
and each occurrence of each AE/SAE/device deficiency
A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
2016N298634_03 CONFIDENTIA L
HZA107116
91The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  inter vention 
administration will be considered and investigated.
The investigator will also consult the Investigator’s Brochure (IB) in his/her 
assessment.
For each AE/SAE/device deficiency , the investigator must document in the 
medical notes that he/she has re viewed the AE/SAE/device deficiency  and has 
provided an assessment of causalit y.
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to GSK. However, it is very  
important that t he investigator alway s make an assessment of causality  for every  
event before the initial transmission of the SAE data to GSK.
The investigator may  change his/her opinion of causality  in light of follow -up 
information and send a nSAE follow -up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
Follow -up of AE/SAE/device deficiency
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  GSK to 
elucidate the nature and/or causalit y of the AE/SAE/device deficiency as fully  as 
possible. This may  include additional laboratory  tests or investigations, 
histop athological examinations, or consultation with other health care 
professionals.
If a participant dies during participation in the study or during a recognized follow -
up period, the investigator will provide the CRO with a copy  of any  post -mortem 
findings i ncluding histopathology .
New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to the CRO within 24 hours of 
receipt of the information.
14.7.5. Reporting of SA Es
SAE Reporting to GSK via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to the CRO will be the electronic 
data collection tool.
2016N298634_03 CONFIDENTIA L
HZA107116
92If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool (see next t able) in orde r to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
After the stud y is completed at a given site, the electronic data collection tool will 
be taken offline to prevent the entry of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report th is information on a paper SAE form (see 
next S ection) or to the medical monitor by telephone.
Contacts for SAE reporting can be found in the SRM.
SAE Reporting to GSK via Paper Data Collection Tool
Facsimile transmission of the SAE data collection tool is the preferred method to 
transmit this information to the medical monitor.
In rare circumstances and in the absence of facsimile equipment, notification by  
telephone is acceptable with a cop y of the SAE paper data collection tool sent by 
overnight mail or courier service.
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE paper data collection tool within the designated 
reporting time frames.
Contacts for SAE reporting can be found in the SRM.
14.7.6. Reporting of SA DEs
SADE Reporting to GSK 
NOTE: There are additional reporting obligations for medical device deficiencies
that are potentiall y related to SAEs that must fulfil lthe legal responsibility  to notify  
appropriate regulatory  authorities and oth er entities about certain safet y 
information relating to medical devices being used in clinical studies. 
Any device deficiency  that is associated with an SAE must be reported to the CRO
within 24 hours after the investigator determines that the event meets the definition 
of a device deficiency .
The CRO willreview all device deficiencies and determine and document in 
writing whether they  could have led to an SAE. These device deficiencie s willbe 
reported to the regulatory authorities and IRBs/IECs as required b y national 
regulations.
Contacts for SAE reporting can be found in the SRM.
2016N298634_03 CONFIDENTIA L
HZA107116
9314.8. Appendix 8: Country -specific requirements
For German y onl yexclusion criterion 8 will be as follows:
Exclusion of participants with QTc > 450 msec or those with any other significant 
abnormality  in the screening 12- lead ECG .
2016N298634_03 CONFIDENTIA L
HZA107116
9414.9. Appendix 9: COVID -19 Measures
Protocol Title: A randomised, double -blind, parallel group, multicentre, stratified, study  
evaluating the efficacy  and safet y of once dail y fluticasone furoate/vilanterol inhalation 
powder compared to once daily  fluticasone furoate inhalation powder in the treatment of 
asthma in participants aged 5 to 17 y ears old (inclusive) currently  uncontrolled on inh aled 
corticosteroids
Protocol Number : HZA107116/ 04 Amendment 4
Compound Number 
or Name:GW685698+GW642444
Brief Title: A double- blind, parallel group stud y to evaluate the safet y and efficacy  of 
fluticasone furoate/vilanterol combination compared to flut icasone furoate in the 
treatment of asthma in participants (aged 5 to 17 years old inclusive )
Study Phase: IIIA
Approval Date: 24-AUG -2020
THIS APPENDIX APPLIES TO ALL CURRENT APPROVED VERSIONS OF 
PROTOCOL HZA107116
Overall Rationale for this Appendix 
COVID -19 pandemic may  impact the conduct and delivery  of clinical studies. Challenges 
may arise from quarantines, site closures, travel limitations and/or interruptions to the 
supply  chain for the investigational product . These challenges may lead to difficulties in 
meeting protocol -specified procedures, including administering or using the 
investigational product , adhering to protocol -mandated visits , laboratory /diagnostic testing
and study  timelines. 
HZA107116 is included in the P aediatric Investigation Plan (PIP) for Relvar™ Ellipta™ , 
with a commitment to deliver to agreed European Medicine sAgency  (EMA) timelines. 
The COVID -19 pandemic may delay study timelines due to low recruitment rates as a 
result of site closures and travel limitations and may lead to a greater number of early 
withdrawals.
2016N298634_03 CONFIDENTIA L
HZA107116
95This protocol appendix outlines measures that may  be applicable for any  site impacted by 
the COVID -19 pandemic and to ease the burden on site staff, subjects and parents by 
allowing flexibil ity in the way  the visits are conducted in an attempt to counter the impact 
of COVID -19 pandemic on recruitment and retention. The purpose of the appendix is to 
provide information on the measures to be taken to protect participants’ safety , welfare and 
rights, promote data integrit yand deliver the study  within the agreed timelines of the PI P. 
These measures will remain in place until study  completion .
Study Procedures During COVID -19 Pandemic
During the special circumstances caused b y the current COVID -19 pandemic, sites should 
consider specific public health guidance, the impact of an y travel restrictions implemented 
by local/regional health authorities and local institutions, and individual benefit /risk when 
making enrollment and treatment decis ions for trial participants.
Clinical investigators should document in site files and in source data, how COVID related 
restrictions or challenges may have impacted study  conduct for any participants. Missing  
or delay edprotocol required data/visits due toCOVID -19 should be noted in participant 
notes and recorded as a COVID -19 protocol deviation. 
Protocol Defined Procedures/Visits:
Where applicable country  and local regulations and infrastructure for home healthcare 
allow, home healthcare may take place at a location other than the clinical trial site to 
perform study  assessments, which may include collection of blood and urine samples, 
measurement of vital signs , weight , spirometry and dispensation and collection of study 
drug (at the discretion of the Investigator). It is the responsibility  of the investigator to 
inform the CRO when this occurs and to document in source notes.
Remote visits may be performed at the participant’s home by qualified study 
personnel, unless the Investigator deems that a site visit is necessary .
Additional unscheduled safet y assessments such as routine blood sampling may be 
performed at the discretion of the Investigator including in the participant’s home, 
if deemed necessary .Biological samples may be collected at a different location, 
other than the study  site (e.g., at participant’s home) by qualified study  personnel 
or at a local medical facility  according to standard operating procedures and 
applicable regulations (see note). Biological samples should not be collected if they 
cannot be processed in a timely  manner or appropriately  stored until the intended 
use. 
Spirometry  may be collected by a home health nurse ,at visits indicated in the SOA, 
to alleviate the burden on subjects of frequent visits to the study  site. The spirometry 
must be done using a Masterscope provided by the spirometry  vendor, ERT (with 
central over -read).  Nurses will be experienced in spirometry and will be trained by 
ERT. 
NOTE : Serial spirometry at Visit 6 must be done in the clinic.
2016N298634_03 CONFIDENTIA L
HZA107116
96If visits to a site/home are not feasible, then the medical evaluation of asthma may 
take place by telemedicine which will use secure video conferences, phone calls, 
and a web portal and/or mobile application as a way of communicating with and 
monitoring the participant’s progress. The CRO will be accountable for working 
with Science 37 (the vendor) to ensure the site has the required equipment, training 
and support for this model and should be notified as soon as possible by the 
investigator that the servi ce is required.
As part of this model, study  visits are completed using the Science 37 platform, 
which is a software interface that connects participants to their investigators and 
study  teams through either a study -issued smartphone or participant’s own device 
(BYOD) model in addition to providing a data collection platform. This technology  
may be used in combination with visits from mobile study  personnel (e.g. mobile 
nurses) to participants’ homes for various lab collections and designated study  
procedur es. 
The study  investigator is responsible for ensuring that the identification, 
management, and reporting of AEs and SAEs are completed in accordance with the 
protocol and applicable regulations. AEs are first reported by participants to the 
investigator/ study  team or may  be identified by  the study  team during interactions 
with the participants via telemedicine encounters. In addition, mobile nurses may 
identify  AEs as well and report them to the investigator for evaluation. 
Additionally , AEs may be identi fied from lab reports, imaging or ECG reports, and 
other records. As determined by the investigator, the appropriate medical 
intervention, therapeutic intervention, and/or support measures are instituted, as 
necessary . Provision of a study -issued smartphon e or the Science 37 app on a 
participant ’s own device allows for study  participants to report AEs at any time. 
Participants can also request a timely secure videoconference with the investigator 
and/or site staff.
The participant should be informed of the plan and any potential risks associated 
with the virtual medium and sign a revised Informed Consent Form if required. 
IRB/Ethics committee should be informed and/or approve of this change in 
approach and the process documented in study  files.
The schedule of study  activities is provided in Table 1.
Study Intervention(s)
If allowed by country  regulation/ethics, then study  intervention (including rescue study 
medication and ancillary  supplies related to IMP administration) can be shipped direct -to-
patient (DTP) from the investigational site to the participant’s home address. The process 
for this shipment must be agreed with the CRO who will provide the relevant 
documentat ion and links to courier sites required to ensure shipments are adequatel y 
temperature controlled (if required) throughout transportation.
The Principal Investigator assumes Good Clinical Practice (GCP) responsibilities for I MP 
handling and the medical control for dispensing to patients. Site Staff should document the 
2016N298634_03 CONFIDENTIA L
HZA107116
97dispensing in the Dispensing/Accountability  Logs adding a comment that this was a DTP 
dispensing. 
Compliance with provisioning and collection of study  drug will be verified through 
observation by  study  staff or trained home healthcare professionals.
In some cases, trial participants who no longer have access to investigational product or 
the investigational site may need additional safet y monitoring (e.g., on withdrawal of an 
active investigational treatment).
Data Management/Monitoring
The eDiary  device provided to the participant may be returned to the home nurse after Visit 
9)/ETD/EW or the participant should be instructed to maintain the device and to return 
them to the site when a visit to the site will be allowed.] 
If on-site monitoring is no longer permitted, the CRO will consider remote Source Data 
Verification/Source Document Review (SDV/SDR) where permitted by the clinical 
site/institution . Remote SDV/SDR will be proposed to study  sites to meet a patient and/or 
critical qualit y need, e.g., to assess participant safety  or to ensure data integrity . In case of 
remote SDV/SDR, the CRO will work with the site to ensure subject privacy . 
eCRF/CRF Final or Interim Sign off Process: The Principal Investigator (PI) is responsible 
for ensuring that the data within the eCRF casebook and any other data sources utilized 
during the study  for each study  participant is complete and consistent with source 
documents throughout the study  (ICH GCP 4.9.1 4.9.2). The PI may sign/re-sign the eCRF 
from any computer/location by accessing the eDC platform using his/her unique eCRF log-
in credentials. The PI  may delegate this activity  to another medicall y qualified and trained 
sub-investigator and this must be documented on the Delegation of Responsibilities (DoR) 
Log. It is recommended that the PI identifies a sub-investigator as a back -up for eCRF 
signatures. The sub-investigator must be appropriately  trained on the protocol and eCRF 
requirements (with training documented), and the DoR log updated accordingl y. 
Essential Document Sign Off Process: If an investigator is unable to print and sign essential 
documents such as Protocol /Amendment signature page then Email approval can be 
accepted b y repl ying to the relevant email that is sent by  the CRO.
2016N298634_03 CONFIDENTIA L
HZA107116
9814.10. Appendix 10: Protocol A mendment History
The Protocol Amendment Summary  of Changes Table for the current amendment i s 
located directly  before the Table of Contents (TOC).
The Protocol Amendment Summary of Changes for the previous amendments 
(Amendment 01 and Amendment 02) is provided below.  
Amendment 01 19-JUN-2019
Overall Rationale for the Amendment: The aim of this amendment is to aid in the 
recruitment of participants in this study . The changes will allow flexibility  to perform 
spirometry  manoeuvres are screening especiall y in the y ounger participants.  
Section # and Name Description of Change Brief Rationale
Spon sor Signature 
PageAmended to indicate new sponsor 
signatoryAmended as there is a 
change in sponsor signatory.
Synopsis and Section 
4 Objectives and 
EndpointsAdded clarity around the primary 
endpoint to indicate which was required 
by the FDA and EMA.Toprovide clarity based on 
regulatory feedback.
Section 6.1 Inclusion 
criteriaInclusion criterion 3 –
Prebronchodilator FEV1.  
The note to this criterion has been 
amended to allow participants who are 
unable to perform their 
prebronchodilator FEV1 at Vis it 1 
another attempt that can be within 7 
days of this visit.   This was amended to allow 
flexibility to the younger 
participants in this study, 
who may find it challenging 
to perform spirometry for the 
first time at the screening 
visit.  
Section 6.1 In clusion 
criteriaInclusion criterion 4: Reversibility 
This criterion has been amended to 
reflect that the waiting time after SABA 
will be within 15 and 40 minutes 
instead of 10 and 40 minutes as in the 
original protocol.  This was amended to allow 
more t ime for the SABA to 
take effect and allow 
participants a better chance 
of demonstrating 
reversibility.
Section 6.1 Inclusion 
criteriaInclusion criterion 8:  Male and Female 
participants
A note has been added to clarify that 
females who are lactating are not to be 
included.  Added based on feedback 
that was received when the 
original protocol was issued.  
An administrative letter was 
produced for sites at the 
time.  
Section 6.2 Exclusion 
criteriaExclusion criterion 6: Obesity 
This criterion has been amended to 
ensure that severely obese participants 
(ie, participants who have a BMI above 
the 99th) are excluded rather than Amended to ensu re that 
severely obese participants 
were excluded as severe 
obesity has an impact on 
respiratory function.
2016N298634_03 CONFIDENTIA L
HZA107116
99Section # and Name Description of Change Brief Rationale
those who classed as obese (ie, had a 
BMI at the 97th centile as in the original 
protocol).
Section 6.2 Exclusion 
criteriaExclusion criterion 8: QTc  
This criterion has been amended to 
indicate that only QTc(F) will be used 
for eligibilit y purpose.  Amended to provide clarity 
and to ensure that sites are 
consistently using one QTc 
formula when assessing a 
participant’s eligibility.
Section 6.2 Exclusion 
criteriaExclusion criterion 10: Relevant habits 
(Tobacco use) 
This criterion has be en amended to 
indicate that participants using e -
cigarettes and who are vaping are also 
excluded. Amended to ensure that all 
tobacco or smoking -related 
use was not allowed.
Section 6.3 
Screen FailuresThis was amended to allow for re -
screening of screen failures up to one 
additional time.  Amended to help with 
recruitment of a difficult to 
recruit population.
Section 9.1.1 Efficacy 
Assessments -FEV1Added that predicted FEV1 values are 
based on ERT standards for 
spirometry.Added for clarity
Section 10.1.1.1.
Sample Size 
Assumptions for 5 -17 
Year Old PopulationCorrected an error and added more 
detail regarding the standard deviation 
assumed for the primary endpoint for 
the 5 -17 years old population.Added following a regulatory 
request from the FDA f or 
more information.
Section 12.7 Appendix 
related to country -
specific changesAdded a change in exclusion criterion 8 
that is applicable to participants in 
Germany only.Added based on feedback 
that was received when the 
original protocol was issued.  
An administrative letter was 
produced for sites at the 
time.  
Amendment 02 10-DEC -2019
Overall Rationale for the Amendment: Asthma is a variable condition especiall y in 
children.  Additionally , spirometry  is a procedure that is often challenging to perform in 
this population and children may  have s ymptomatic asthma even when they  appear to 
have normal lung function.  The changes in this amendment take into account the 
varia bility  in asthma b y allowing re -screening, and also by  increasing the maximum 
permitted FEV 1at screening and randomisation to 100% predicted normal.   These 
changes are expected to help with recruitment of this population.
2016N298634_03 CONFIDENTIA L
HZA107116
100Section # and Name Description of Change Brief Rationale
Schedule of Activities 
(SOA)Visit 4 and Visit 5 will become optional 
parent only visits, and as a result FEV 1
measure will only need to be done if 
the participant attends the clinic.   
A footnote is added to indicate this.  
Also, the footnote states if the 
participant does come to the clinic with 
the parent, and the visit occurs in the 
morning (6.00am to 11.00am) then the 
spirometry measurement should be 
performed. If only the parent attends, 
then this can be at any time of day.      This was amended to give 
participants the option of not 
attending to reduce burden 
on younger participants 
having to miss more school 
days and come to the site.  
Parents will need to come to 
collect study treatment.
Section 5.1, Overall 
Study DesignFigure 1 –Study Schematic updated to 
add footnotes relating to Visits 4 and 5
Last paragraph in S ection updated with 
details around Visits 4 and 5. And 
amended wording to indicate which 
visits need to be morning visits.Changes made for 
consistency and clarity.
Section 6.1 Inclusion 
criteriaInclusion criterion 1 –Age
Changed ‘at the time of signing the 
informed consent’ to ‘at the time of 
screening’.This was amended for 
consistency as participants 
are stratified by age at 
screening.
Section 6.1 Inclusion 
criteriaInclusion criterion 3 –
Prebronchodilator FEV 1.  
The upper limit of the range has been 
changed from ≤90% to ≤100%  This was amended to reflect 
that the younger population 
often have a pre -
bronchodilator FEV 1
predicted that is normal b ut 
they may still have 
symptomatic asthma. This 
change was therefore to aid 
recruitment of symptomatic 
asthma participants who 
demonstrate reversibility but 
who may have normal lung 
function.  
Section 6.1 Inclusion 
criteriaInclusion criterion 3 –
Prebro nchodilator FEV 1.  
The note to this criterion has been 
amended to allow participants who are 
unable to perform their FEV 1at Visit 1 
another attempt that can be within 14 
days of this visit. This is extended from 
the 7 days that was allowed in 
amendment 1. This was amended to allow 
flexibility to the younger 
participants in this study, 
who may be unfamiliar with 
the procedu re and may find 
it challenging to perform 
spirometry for the first time 
at the screening visit.  
2016N298634_03 CONFIDENTIA L
HZA107116
101Section # and Name Description of Change Brief Rationale
Section 6.1 Inclusion 
criteriaInclusion criterion 3 –Reversibility.  
The note to this criterion has been 
amended to allow participants who are 
unable to a ttempt to perform their FEV 1
at Visit 1 another attempt that can be 
within 14 days of this visit.   This was amended to allow 
flexibility to the younger 
participants in this study, 
who may be unfamiliar with 
the procedure and find it 
challenging to perform 
spirometry for the first time 
at the screening visit.  
Section 6.3 
Screen FailuresThis was amended to allow for re -
screening of screen failures. Asthma is a variable 
condition especially in 
children, thus participants 
who have screen -failed 
could be re -screened at a 
later date if the severity of 
their asthma has changed. 
This will help recruitment of 
younger participants. 
Section 8.1.2 Amended t ext to indicate that only 
QTcF is used for the ECG.  
A footnote was added to the SOA to 
indicate that the QTc should be based 
on a single or averaged QTc values of 
triplicate ECGs.Amended for clarity.
Section 9.1.1 Amended the visits in 4th
paragraph.
Removed reference to ERT in 5th
paragraph. Standardise wording
Added Quanjar (2012) 
for calculation of 
predicted normal FEV 1. 
General throughout Added Albuterol.  Standardise wording to 
reflect the fact that 
salbutamol is known as 
albuterol in USA and s ome 
other countries.
Amendment 03 31-JAN-2020
Overall Rationale for the Amendment: As Visit 4 is the first visit after randomi sation 
to study  treatment ,it is considered an important visit at which to collect clinical data .
Section # and Name Description of Change Brief Rationale
Sponsor Signatory Change to the sponsor signatory 
department detailsRevision made due to 
organisational changes.
Schedule of Activities 
(SOA)Visit 4 will no longer be an optional 
parent only visit.  As Visit 4 is the first visit 
after randomization to study
treatment ,it was considered 
2016N298634_03 CONFIDENTIA L
HZA107116
102Section # and Name Description of Change Brief Rationale
The participant will need to attend this 
visit where clinical assessments as 
indicated in the schedule of activities 
will need to be assessed. 
Thus ‘Footnote 2’ has been amended 
to remove Visit 4.by the regulators to be an
important visit at which to 
collect clinical dat a.   
Section 5.1, Overall 
Study DesignFigure 1 –Study Schematic updated to 
remove reference to Visit 4 being an 
optional parent only visit.
Last p aragraph in this S ection 
amended to correctly reference Visit 4.Changes made for 
consistency and clarity.
Section 7.7.1, 
Prohibited 
Medications and Non -
Drug TherapiesThe changes made to Section 7.7.1 
included the addition of the following 
note and new t ext (red text denotes 
new text):
•Note:  Participants should be treated 
as appropriate for asthma 
exacerbations without requirement to 
withdraw the participant from the study. 
Steroids will be an exclusion from 
randomisation if administered during 
the run -in period (apart from FP). 
However, they should never be 
withheld if deemed necessary. 
•Use of the following medications is 
prohibited according to the timeframes 
indicated unless they are deemed 
necessary to treat an asthma 
exacerbation or another condition 
appropriately:
•From screening visit (Visit 1) to Visit 9: 
LTRAs, ketotifen, nedocromil sodium, 
orally inhaled sodium cromoglycate, 
SABA/short -acting muscarinic 
antagonist (SAMA) combinations (e.g. 
Combivent), and inhaled corticosteroids 
(except for FP which is given during the 
run-in).    To provide further clarity on 
the use of steroids.
Section 9.1.1 FEV1 Fourth paragraph amended text to 
correctly reference Visit 4.Changes made for 
consistency and clarity.